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ABSTRACT 
USE OF MONOCLONAL A-9-TETRAHYDROCANNABINOL ANTIBODIES 
CHEMICALLY BOUND TO A POLYSTYRENE SURFACE USING 
GLUTARALDEHYDE FOR THE PURPOSE OF EXTRACTING 
A-9-TETRAHYDROCANNABINOL AND A-9-TETRAHYDROCANNABINOL 
CARBOXYLIC ACID FROM POSTMORTEM WHOLE BLOOD SAMPLES FOR 
ANALYSIS BY GAS CHROMATOGRAPHY MASS SPECTROMETRY 
by Thomas Sidney Pittman 
May 2008 
Quantitations of drugs and their respective metabolites in postmortem blood 
samples using gas chromatographic instrumentation is a primary analytical practice used 
to determine if drugs played a role in or were the cause of a victim's death. Postmortem 
blood samples often prove difficult to work with due to interfering substances formed 
during the putrefaction process. Attempts to eliminate interfering substances with present 
day extraction methods can be time consuming, costly and often ineffective when dealing 
with drugs that exhibit toxicity or impairment at very low concentrations. This study was 
conducted using monoclonal antibodies chemically bound to a polystyrene surface to 
extract A-9-Tetrahydrocannabinol and its major carboxylic acid metabolite from 
postmortem blood samples. The device was a Falcon® cell culture flask with 12.5 cm2 of 
surface area. To each flask was added a 5% solution of glutaraldehyde followed by 5 
ug/ml of antibody. Binding studies for THC and THCA using ELISA reagents resulted in 
an average binding capacity of > 200 ng/ml for individual analytes. When both analytes 
were added at equal concentrations, binding capacity for THCA fell as the concentration 
n 
for THC was increased. Percent yield studies demonstrated an average 54% yield for 
THC and an average of 49% yield for THCA. Paired t test for THC demonstrated a 
significant difference in two runs where t o.i(8) = 3.355 and paired t values were 4.384 and 
6.034. Two runs for THCA were t .01(27) = 2.771 had paired t values of 9.596 and 8.827 
which also demonstrate a significant difference. All samples reported as "None Detected" 
for THC or THCA by MCL were found to contain no THC or THCA by this extraction 
method. Ten samples reported by MCL as "unable to report due to interfering 
substances" for THC were run twice with two samples showing no THC detected and 
eight of the samples showed no interferences present when using this extraction device. 
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CHAPTER I 
INTRODUCTION 
Chromatographic analysis for and quantitations of drugs along with their 
respective metabolites in postmortem blood samples is a primary analytical practice used 
in forensic toxicology to determine whether drugs played a role in or were the cause of a 
victim's death because drug testing is the only objective means to determine use 
(Niedbala et al., 2001). Postmortem blood samples often prove a difficult matrix to 
analyze due to interfering substances produced during the natural putrefaction process 
that begins shortly after death. Other natural constituents of whole blood or other drugs 
can also cause problems when working with postmortem blood samples. 
Liquid/liquid extraction schemes of drugs from biological matrices where first devised in 
the 1850s (Levine, 2003) and the process and chemistry of such extractions of drugs from 
postmortem biological samples remain basically the same today. Procedures with added 
steps can be used in efforts to remove interfering substances such as back extractions of 
samples into acids or alkaline buffers and then a second extraction at an acid or alkaline 
pH, but these steps add time and cost to the process. The following is an example of 
how a back extraction would proceed. To a 16x125 screw cap glass tube, 1-2 ml of 
sample would be buffered to pH 4.5 with 1-2 ml of an acetate buffer, vortexed and then 
8-10 ml of an appropriate organic solvent added. The sample would then be shaken or 
rotated from 15 to 30 min followed by centrifugation for 20 min. The organic phase 
would be transferred to a clean tube and 1-2 ml of an alkaline buffer added to the organic 
solvent. The solvent would again be shaken or rotated and centrifuged. The organic 
phase this time would be discarded and an acidic buffer added to the aqueous phase. An 
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appropriate organic solvent would be added, 8-10 ml, and the sample shaken or rotated 
for a third time followed by centrifugation. The organic layer would be transferred to a 
new tube and evaporated to dryness. The extract would be dissolved in a desired 
injection solvent for analysis. There have now been three extraction steps, several 
milliliters of buffer and up to 20 ml of an organic solvent used in this procedure. 
Depending on the number of calibrators, controls and samples, a back extraction 
procedure may take 4-6 hours to complete. 
Percent recovery of drugs becomes an issue with the use of multiple extraction 
steps. Many drugs encountered today result in impairment or toxicity with 
concentrations in the ng/ml range and few extraction procedures achieve 100% recovery. 
With each extraction step, a portion of the drug is lost which may result in not being able 
to detect, confirm or quantitate a drug during analysis. 
Solid phase extraction techniques (SPE) provide an alternative to liquid/liquid 
extractions for drugs in biological matrices. Forensic SPE procedures were initially 
designed for extraction of illicit drugs from urine samples for confirmation testing 
required by employee drug testing programs. The use of SPE columns is also used to 
extract drugs from serum or plasma, but these two matrices do not present the same type 
problems found with postmortem whole blood samples. 
SPE is done by either negative or positive pressure devices. Negative pressure 
systems have a vacuum chamber that pulls the sample through the columns. A positive 
pressure system simply pushes the sample through the columns. Both type SPE systems 
possess inherent problems of clogging when postmortem whole blood is the sample 
being extracted. Degradation products in whole blood often cannot be centrifuged into a 
pellet or filtered out of the sample and it is these components that clog SPE columns. 
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Once a column is clogged, it can no longer be used and the sample is lost. 
There are critical steps in SPE that makes the procedure work most efficiently. 
One is the wetting of the columns with water and an alcohol prior to adding the sample. 
Next is the controlling of how fast the sample flows through the column to ensure the 
analyte of interest is retained. The third step is the drying of the column prior to elution. 
If any of the steps is not strictly controlled, the extraction procedure will fail. 
Time consuming steps such as the need to make fresh reagents for daily use and 
maintenance of equipment add cost to SPE methods, and elution of interfering substances 
remain problematic as in liquid/liquid extractions. 
Another issue that arises from present extraction procedures is maintenance of 
chromatographic instrumentation. The principle behind gas chromatography is to 
volatilize an injected sample and use a gas to move the constituents through the column 
achieving separation. Heated injection liners of gas chromatographs and 
chromatographic columns are subject to contamination from various breakdown products 
of blood and other type biological samples that do not volatilize and adhere to the 
injection liner and the front several inches of the column. Analytes of interest that adhere 
to the these contaminants often fail to elute, show a reduction in concentration or poor 
peak shape making quantitations difficult at best. The glass liners often have to be 
discarded and the at least 18 inches from the front of the column cut to restore quality 
chromatography. Once a column has been cut, retention times of all analytes will change 
requiring altering SIM windows or gas chromatographic settings changed to maintain 
established retention times. 
Degradation products that do flow through the column will eventually result in a 
loss of mass spectral sensitivity. Compounds are deposited on the metal lenses of the 
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mass spectral source causing a film to develop that interferes with the electronic tuning of 
the mass spectrometer. Once the internal stainless steel lenses have become sufficiently 
dirty and the instrument cannot be Autotuned to specifications, a cleaning of the lenses is 
necessary. Cleaning requires shutting down the instrument for at least one day to 
accomplish. After cleaning, the instrument must be recalibrated to ensure the cleaning 
was successful. If not, the cleaning must be repeated. When many whole blood samples 
are routinely analyzed, cleaning becomes a common routine that requires an inventory of 
expensive replacement parts that are of one time use or are not amenable to cleaning. 
Loss of sensitivity due to dirty extractions is a major concern when analyzing drugs such 
as marijuana that play a role in accidental deaths due to impairment of an individual's 
central nervous system. 
Therefore, there is a need for a simple, inexpensive and robust device for 
extraction of drugs from postmortem blood samples that does not suffer from or that will 
significantly reduce problems with interfering substances. The chemical binding of 
antibodies to a polystyrene surface for the purpose of extracting a drug from postmortem 
blood samples is a feasible theory to the approach, possibly reducing many if not all the 
problems discussed above. 
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CHAPTER II 
REVIEW OF LITERATURE 
Marijuana 
Marijuana is the common name given to the plant Cannabis sativa. There are 
reportedly some 400 chemicals in marijuana with approximately 61 being classified as 
cannabinoids (Marnell, 2006). Historically marijuana has been used by man for 
thousands of years. The plant has provided fibers from the branches and stems for ropes, 
clothing, and sails for ships as well as food from seeds and oils found in the flowering 
parts of the plant. Marijuana was used as medicine in China and India as early as 3000 
B.C. 
Marijuana is not a native plant to North America (Marnell, 2006). The plant was 
introduced by Europeans colonizing North America and grown as a cash crop. The plant 
grew well in most all areas of North America and thus successfully spread across what is 
today the United States. Marijuana continued to be grown as a cash crop in the United 
States until the around 1937 when the Federal government became concerned about its 
abuse as a drug and passed the Marijuana Tax Act in an attempt to stop the growing and 
The psychoactive constituent in marijuana is A-9-tetrahydrocannabinol (A-9-THC) and is 
classified mainly as a central nervous system hallucinogenic although the psychological 
effect of the drug varies from person to person and by dosage (Huestis, 2003). The 
concentration of A-9-THC considered to cause central nervous system impairment 
resulting in an individual's inability to safely operate a motor vehicle is considered 2 
ng/ml and above in the United States and other countries (Garriott et al., 1986; McBay, 
1988; Samyn et al., 2002; Lin & Lin, 2005). This means on any given analysis of 
marijuana for purposes of determination of impairment of an individual a GC/MS with 
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ectron impact (EI) mass spectral instrument the limit of detection (LOD) and limit of 
quantitation (LOQ) must be less than 2 ng/ml to ensure that a quantitative result of 2 
ng/ml is accurate since marijuana is the most abused illegal drug in the majority of 
countries including the United States (Mason & McBay, 1984; Crouch et al., 1993; 
Niedbalaetal.,2001). 
The pharmacodynamics of marijuana show several modes of action (Hollister, 
1992). The human brain demonstrates high stereospecific receptors for the levo (-) 
isomer of A-9-THC with some five times the potential effect on the user when compared 
to the dextro (+) isomer. Five distinct areas of the brain have been identified with the 
levo specific receptors. 
A-9-THC is highly lipophilic and produces effects on cell membranes similar to 
several other drugs of different classifications such as ethanol, LSD, amphetamines and 
morphine. These differing actions make it difficult to classify marijuana within a drug 
group. 
Smoking is the most common means of introducing A-9-THC into the central 
nervous system. Peak concentrations of 19-26 ng/ml were reached within 10 min of 
smoking a cigarette containing 10 mg of A-9-THC (Agurell et al., 1973). These levels 
decreased to less than 5 ng/ml within 2 hours. Other studies have shown peak 
concentrations of A-9-THC ranging from 46-188 ng/ml following smoking of a single 
marijuana cigarette (Rosenfeld, Bowins, Roberts, Perkins & MacPherson, 1974; Mason, 
A.P., Perez-Reyes, M., McBay, A.J. & Foltz, R.L., 1983 & Kelly et al., 1993). In these 
studies, the concentration levels of A-9-THC fell to or below 5 ng/ml within a two hour 
period. 
Oral ingestion of marijuana after being cooked shows much slower absorption 
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rates via the gastrointestinal tract with peak blood concentrations being reached in 1-3 
hours. The peak concentrations are lower than levels seen in smoking only averaging 6 
ng/ml when 20 mg of A-9-THC was ingested (Baselt, 1982). 
A major problem that exists in the extraction of marijuana for analysis at these 
levels is the inability to eliminate interfering substances during the extraction process in 
many samples. A-9-THC is extracted most efficiently in a liquid/liquid extraction at an 
acid pH of 4.5 (Chu & Drummer, 2002). Acidic extracts tend to produce "dirty" extracts 
due to interaction with and denaturing of proteins. Neutral compounds and lipids are also 
extracted more efficiently into organic solvents at an acid pH adding to the possible range 
of interfering substances in the final extract. This is the rational behind using a back 
extraction to reduce unwanted compounds when performing an extraction for acidic 
drugs. Back extractions will improve the chromatography by eliminating some 
contaminants, but the problem arises whenever extraction efficiency of a drug is poor and 
the expected concentration is in the ng/ml range. 
SPE extractions where both A-9-THC and A-9-THCA are extracted using the 
same column also use an acidic elution solvent for the A-9-THCA resulting in the same 
problems. Some SPE procedures have proven successful for extracting both analytes 
from the same column (Moeller, M.R., Doerr, G. & Warth, S., 1992; D'Asaro, 2000; 
Gustafson, R.A., Moolchan, E.T., Barnes, A., Levine B., & Heutis, M.A., 2003) but with 
plasma samples and not whole blood samples. Compounds that remain on the column 
following initial washing steps at a neutral pH for A-9-THC are eluted by the acidic 
solvent into the final extract of A-9-THCA. These interfering substances are often 
responsible for failed analyses in samples containing low concentrations of A-9-THC. 
A key requirement of confirmations is ion ratios that must fall within a specified 
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range to be considered acceptable and the drug confirmed present. Interfering substances 
are the reason most analyses fail in not meeting the ion ratio criteria. Methods for whole 
blood extractions that have proven reliant for confirmation and meeting ion ratio criteria 
often combine extraction protocols of liquid/liquid and SPE with GC/MS analysis 
(Thompson & Cone, 1987; Felgate & Dinan, 2000). The need to use to separate methods 
is time consuming and expensive. 
Antibodies 
Antibodies are "Y" shaped glycoproteins made up of two heavy chains and two 
light chains bound together by disulfide bonds (Kindt, Goldsby & Osborne, 2007). The 
light chains and heavy chains form two binding regions located at their two amino 
terminal ends that are highly variable in their amino acid sequence. These highly 
variable regions provide specificity for binding to most any molecule, including metals 
(Wylie et al., 1992; Love et al., 1993). 
Antibodies treated with either the enzymes pepsin or papain result in particular 
fragments. Antibody treated with pepsin result in fragments called "Fab" and "Fc". The 
Fab fragments consist of the light and heavy chains that form the upper area containing 
the two binding sites as individual pieces. The Fc fragment is the lower portion or tail of 
the antibody consisting of two heavy chains. When treated with papain, the only 
fragment recovered is the "F(ab')r which is the two amino terminal ends still attached by 
disulfide bonds. The biological role served by antibodies is to bind a specific area or 
epitope located on an antigen and aid in its' destruction or removal from the body. 
B cells are formed within and released from bone marrow with each B cell 
carrying antibodies bound to their cell membranes. The B cells are referred to naive since 
they have yet to encounter antigen that has an epitope that will bind their specific 
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antibody. When these B cells come into contact with an antigen possessing an epitope 
that matches the binding area of the antibody, the B cells are up regulated and begin to 
divide. The new cells produced become either memory B cells or plasma cells. 
Plasma cells secrete antibodies identical to the ones found on the original B cell. 
These cells can be isolated and used for the purpose of producing antibodies against 
specific analytes of interest such as drugs or classes of drugs. 
For a substance to be immunogenic it must have a molecular weight around 2000 
daltons or larger. Smaller molecules will not evoke an immune response that will result 
in the production of antibodies. Most drugs do not have molecular weights in that range 
and must be bound to a larger protein structure (Smith, 1999). Bovine serum albumin 
(BSA) and bovine thyroid globulin (BTG) are two proteins used for attachment of drugs 
through linking molecules used to produce an immune response adequate for the 
production of antibodies. 
To facilitate the drug to act as the epitope, spacer molecules are placed between 
the drug and protein so the drug is not located directly on the protein thereby increasing 
the chances of the drug itself binding antibodies on B cells. The protein-drug complex is 
injected into a suitable host such as a goat or rabbit and the immune response of the host 
animal is allowed to proceed. Some portion of the drug or the entire drug molecule may 
act as an epitope that binds an antibody with sufficient affinity resulting in cellular 
division of plasma cells that will produce antibodies specific for that drug structure. 
Plasma cells that produce the most specific antibodies are isolated from the host 
animal and mixed with mouse tumor cells to form hybridomas. These hybridoma cells 
are cultivated and continue the production of antibodies. Next the hybridoma cells are 
separated and screened to determine which cell line is producing the most specific 
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antibody. This specific cell line is isolated for culturing and further purification of its 
antibodies. Antibodies that come from a single cell line are called monoclonal antibodies 
and demonstrate the best specificity for drug assays. 
Immunoassay Methods 
Catt and Niall (1967) were one of the first to report on using a solid support for 
immobilization of antibodies for use in radio-immunoassays (RIA). The technique of 
binding antibodies to a solid surface for the isolation or testing of presence of specific 
analytes of interest has since found widespread use in various scientific disciplines. Most 
of these immunoassay or affinity techniques were initially used for the purification of 
proteins, hormones and other ligands of interest in biochemistry and diagnostic and 
clinical chemistry testing (Hage, 1998). An example of a clinical test is the analysis of 
fibrinogen in plasma. Here a specific anti-fibrinogen antibody is used to capture 
fibrinogen dissolved in an aqueous solution similar to plasma as it flows through a 
column. Other constituents that are not bound by the ligand are washed from the column 
prior to switching solvents to elute the fibrinogen. The fibrinogen can now be quantitated 
by a UV/VIS detector. 
RIA methods led to the development of several other immunoassay techniques. 
All these methods take advantage of specific antibodies to achieve the desired result of 
screening for the presence and/or quantitation of specific analytes. Enzyme multiplied 
immunoassay technique (EMIT), fluorescent polarization immunoassay (FPIA), cloned 
enzyme drug immunoassay (CEDIA) and enzyme linked Immunosorbent assay (ELISA) 
are all techniques used in the forensic field as screening assays for illicit and therapeutic 
drugs. The forensic field uses such techniques for the expressed purpose of screening for 
the presence of illicit drugs and not for quantitation or confirmation as seen in the clinical 
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area. 
Affinity Chromatography 
Affinity chromatography has been an analytical method since around 1910 (Axen, 
Porath & Ernback, 1967). The purpose of the technique is to separate specific molecules 
from all others within a complex matrix. A key to using antibodies bound to a solid 
surface is that the system can be used over and over (Kim, H.O., Durance, T.D., & Li-
Chan, E.C., 1999). Such devices used in a forensic setting could only be used once 
which is a reason for development of a simplified device at low cost. 
Initially, the method was used to isolate and purify large biomolecules such as 
proteins, carbohydrates and nucleic acids. The first solid supports for affinity ligands 
were polysaccharides activated using cyanogen bromide (Axen et al., 1967). More 
recently affinity chromatography has been applied to the isolation of drugs from either 
humans or in food products from animals. Haagsma and van de Water (1992) used 
affinity chromatography for isolating antibiotic residues in food products generated from 
animals. Identification of drugs in human urine using an online immunoaffinity method 
coupled with high performance liquid chromatography mass spectrometry was performed 
by Rule and Henion (1992). 
Webb et al. (1996) developed an immunoaffinity extraction technique for the 
analysis of LSD which was also coupled with a high performance liquid chromatographic 
system, but the experiments demonstrated poor consistency between analyses. Their 
study used an affinity gel made from Protein A Sepharose CL-4B containing antiserum 
against LSD. Each cartridge contained 0.36 g of the gel and 0.2 ml urine was added for 
analysis. The column was rinsed prior to elution of LSD with phosphate buffer, water 
and 0.5 ml absolute ethanol. LSD was eluted with 1.5 ml ethanol, dried and then 
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reconstituted with 100 uL of mobile phase. The internal standard, methysergide, was 
added following extraction which may account for the inconsistent results. The only 
publication using gas chromatography with an EI mass-spectrometer found to date is 
Bagnati et al. (1991) who identified zeronal and the metabolite P-zeronal in calf urine 
using a gel based extraction method. 
There are several methods that have been developed for the binding of molecules 
to a solid matrix such as a polystyrene surface for the subsequent binding of specific 
types of ligands (Hermanson et al., 1992). The manner and orientation of ligand 
attachment to the matrix is one of the most important questions to consider prior to 
developing an affinity based extraction device. The best type of attachment is covalent 
bonding between the surface and the ligand (Nisnevitch & Firer, 2001). This ensures the 
ligand remains in place during wash steps that remove unwanted substances. Secondly 
the ligand must also remain attached during the elution of the analyte of interest so that 
the ligand itself does not become a contaminant. Hale (1995) used an iminodiacetate 
resin in conjunction with C0CI2 and H2O2 for attachment of antibody specifically using 
the Fc region to ensure proper orientation of binding sites. 
Many of the methods developed for use by affinity chromatography for 
subsequent purification and identification use some form of a high performance liquid 
chromatography system (HPLC) coupled with various types of detectors such UV/VIS, 
diode array or multiple mass spectrometer techniques (Johns et al., 1996; Hage, 1998; 
Thompson & Cone, 1987). 
Polystyrene is a matrix that possesses a hydrophobic surface that contains no 
functional groups for direct attachment of either spacer molecules or ligands (Hermanson 
et al., 1992). The surface may be treated with alkaline buffers in the pH range of 9.0 to 
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9.5 making the surface amenable to passive, noncovalent absorption of affinity ligands 
such as antibodies. The problem that arises with this type preparation is there is no way 
to ensure the ligand will not be removed from the surface during experiments. 
Glutaraldehyde has been used for many years as a linking molecule for attaching 
proteins to polystyrene surfaces (Klasen et al., 1982). Polystyrene plates can be 
modified with glutaraldehyde to provide a covalent linking molecule for attachment of 
proteins. The chemical reaction of binding one end of glutaraldehyde to the polystyrene 
is accomplished at an acidic pH by producing radical vinyl bonds between the 
polystyrene and one end of the glutaraldehyde molecule (Hermanson et al., 1992). 
Antibodies are then attached to this layer of glutaraldehyde molecules at an alkaline pH 
(8-9.5) with chemical bonds formed between the free aldehyde groups with amino groups 
located on the antibody. This is a simple procedure that does not require any specialized 
instrumentation or chemicals and can be carried out in most all laboratories with ease. 
The one drawback to the procedure is the orientation of antibodies cannot be controlled. 
Thus, a sufficient concentration of antibodies and surface area are required to ensure 
sufficient numbers of binding sites will be available for drug capture. 
Another consideration of orientation is positioning of antibody in a device. The 
issue becomes how far an antigen may have to diffuse when dealing with a flat surface 
(Stenberg & Nygren, 1988). Once antibodies in a given area are bound with antigen, 
then unbound antigens must be able to diffuse to non-bound antibodies. If this distance is 
too far, then a reduction in percent yield can be expected. 
Enzyme Linked Immunosorbent Assay 
Enzyme linked immunosorbent assays were initially developed for special clinical 
applications followed in time for specific drug quantitations in serum or plasma and for 
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drug screening in urine and whole blood for drugs of abuse. ELISA assays work based 
on competitive binding between analyte and enzyme tagged analyte for antibody binding 
sites in reaction wells. In general, the more analyte present the more antibody sites will 
be bound by analyte. An enzyme tagged with the same analyte of interest will bind 
antibody sites that are free. A color reagent is added as a substrate for the enzyme to 
create a color change. The reaction is stopped using a solution designed to inhibit the 
enzyme and an absorbance reading taken of each well at a specified wave length of light. 
The lower the absorbance value the higher the concentration of analyte in the sample. 
Conversely, the higher the absorbance value the lower the concentration of the analyte. 
Each assay kit has a cutoff threshold standard at a given concentration or set of 
calibrators for determination of a positive sample and concentration in clinical testing. 
A clinical ELISA test developed to quantitate mannose-6-phospahte receptors in 
cells is an example of using immobilized antibodies for the capture and purification of 
proteins of interest (Suresh et. al, 2002). In this study, goat antibodies specific for protein 
receptors MPR 300 and MPR 46 were bound to each well of 96 well microtiter plates. 
Purified membrane extracts were added to designated wells and then washed prior to 
adding anti-goat IgG conjugated to alkaline phosphatase. Methods such as this use an 
enzyme and substrate to generate a color which is measured at specific wave lengths of 
light for quantitative purposes. Clinically it is acceptable to rely on such an assay 
without further testing that the assay is actually measuring the analyte of interest based 
solely on the specificity of the antibodies produced. Such is not the case in forensic 
science. 
ELISA testing in forensic science is used for the purpose of screening biological 
samples for the presence of specific drugs or drug classes (Levine, 2003). The assays use 
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monoclonal or polyclonal antibodies developed against a specific drug or specific drug 
class that demonstrate sufficient cross reactivity to other drugs within the same class. 
This type testing is used strictly for drug screening due to the phenomenon of cross 
reactivity. As an example immunoassay kits designed for amphetamines will cross react 
with several over-the-counter medications that contain drugs very similar in molecular 
structure to the amphetamines resulting in presumptive positive results when present in 
biological samples being tested (Kelly et al., 1993). 
When testing is performed for a class of drugs such as opiates, barbiturates or 
benzodiazepines a positive result only indicates the possible presence of one or more of 
the drugs within the class, but does not indicate which drug or drugs is/are actually 
present. This is the reason behind confirmatory testing so that the drug(s) may be 
positively identified by a more specific methodology such as gas chromatography-mass 
spectroscopy. 
Quantitations of drugs by ELIS A as well as other immunoassay techniques is 
forensically unacceptable due to cross reactivity when it is not known which specific 
drug(s) of a given class of drugs is present. Each drug within a class cross reacts at a 
different binding percentage based on its concentration as compared to the drug for which 
the antibody was specifically designed against. This makes quantitations of drugs 
basically impossible when using ELISA test kits as a testing method in forensic settings. 
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CHAPTER III 
MATERIALS AND METHODS 
Phase I 
Experimental Protocol 
This project was designed to develop an extraction device that can be easily 
adopted for use with a gas-chromatograph coupled to an EI+ mass-spectrometer along 
with other typical chromatographic instrumentation used in forensic laboratories. 
An experimental protocol was developed to test the hypothesis that A-9-THC 
within a complex biological matrix could be bound by antibodies specific for A-9-THC, 
remain bound during several washing steps and subsequently recovered from a 96 well 
ELISA microtiter plate for qualitative analysis by GC/MS. 
The second step in the research protocol was immobilization of sufficient A-9-
THC monoclonal antibodies onto a solid surface of polystyrene using glutaraldehyde as 
the linking molecule. One goal of this project was to develop a device of sufficient 
surface area to which antibody specific for A-9-THC could be chemically bound without 
any sophisticated equipment. The device had to be capable of holding 1 to 2 ml of a 
biological matrix in a manner to ensure exposure of analyte to antibody. 
Third a rinsing protocol designed to eliminate interfering substances was established 
without releasing the bound drug from antibodies. Once interfering substances were 
removed, the final step in preparation for analysis was the release of all analyte from 
antibodies using a minimum volume of an organic solvent. At this point, a minimum 
volume of solution containing primarily the drug and/or metabolites of interest was 
evaporated and prepared for analysis by GC/MS. The purified extraction was 
accomplished using a short incubation period, limited number of rinse steps, and a 
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minimum volume of organic solvent. 
Drug Standards 
Standard solutions of A-9-THC at a concentration of 1.0 mg/ml and A-9-THCA at 
a concentration of 1 mg/ml in methanol were purchased from Cerilliant (Round Rock, 
TX). These standard solutions were used to make stock and working standard solutions 
for use in all experiments. Deuterated standards of A-9-THC-D3 and A-9-THCA-D3 
were also purchased from Cerilliant containing 100 ug/ml of analyte for use in 
quantitation A-9THC and A-9-THCA. Stock solutions for all analytes were made from 
the purchased standards. Stock drug solutions where used to prepare working solutions 
of individual analytes for spiking all calibrators and controls. Postmortem blood samples 
from the Mississippi Crime Laboratory were spiked with internal standard solutions. 
ELISA Kit Testing 
An ELISA Cannabinoid kit was purchased from Immunalysis (Pomona, CA) for 
the initial phase of the project. The ELISA kit contained five 96 well plates with 12 
removable rows of cannabinoid antibody coated wells with eight wells per row. Each 
coated well had the capacity to hold approximately 300 uL of total fluid. Individual 
plates were designated based on concentration of analyte added and incubation time 
during initial experiments. The kit also came with THC derivative solution conjugated to 
horseradish peroxidase, synthetic negative blood, 3, 3', 5, 5' tetramethylbenzidine (TBM 
chromogenic substrate) and 1 N hydrochloric acid as a stopping agent. 
The first experiment was run to establish that the kit would perform as described 
by the manufacturer. Synthetic blood was spiked with A-9-THC at a concentration of 25 
ng/ml and added to seven rows with the first row representing a negative sample. 
The second experimental protocol followed was based on the manufacture's 
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instructions with the exception of sample dilution prior to analysis. Volumes of sample 
(125 uL) and THC-conjugate added to each well were also altered to achieve 
approximately 1 ml of sample per eight wells for binding studies. The decision not to 
dilute the samples was necessary for later determination of analyte percent yield by 
GC/MS analysis. The protocol used for the first two experiments were as follows: 
1. 125 uL of sample was added to a designated well. 
2. Plates were incubated for 1 hr at room temperature. 
3. Plates were washed five times with 250 uL DI water using an 
automated plate washer. 
4. Following initial wash steps, 125 uL of THC-conjugate derivative was 
added to each well. 
5. Plates were incubated for 1 hr at room temperature and then washed 
five times with DI water using an automated plate washer. 
6. Plates were inverted and slapped on dry paper towels to ensure no 
THC-conjugate remained and wells were dry of fluid. 
7. 125 uL of TMB chromogenic substrate was added to each well and 
incubated in the dark at room temperature for 30 min. 
8. 125 uL of IN HC1 (stop reagent) was added to each well and the plates 
tapped several times to insure complete mixing. 
9. Developed color of all wells was measured using a Victor 3 (Perkin 
Elmer, Shelton, CT) automated plate reader at 450 nm and 
absorbances recorded. 
The protocol for the analyte recovery experiments was as follows: 
1. Perform steps 1 -6 as described above. 
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2. 250 uL of acidic methanol, hexane or N-butyl chloride was added to 
each well of their respective plates and incubated for 1 hr. 
3. Recovery of solvent from a single row of eight wells was collected and 
placed in a single labeled 16x125 mm screw cap tube. 
4. Tubes were refrigerated until ready for analysis. 
The third experiment performed was addition of A-9-THC, A-9-THCA and their 
respective deuterated internal standards at 25 ng/ml each to duplicate rows in order to 
determine the antibodies would bind and be retained through the method protocol. 
Incubation Period Determination for Percent Yield Study 
An optimum incubation period for analyte recovery was performed by 
incubating spiked samples for 15, 30 and 60 min in the microtiter plates. All analytes 
were added to specified rows of wells at a concentration of 25 ng/ml and run through the 
method. 
Once the optimum time frame was established, this time was used for the 
remainder of the ELISA experiments. Four drug free synthetic blood samples of 1 ml 
each were spiked individually with A-9THC, A-9-THCA and their respective deuterated 
internal standards at concentrations of 25 ng. Plates were then run through the recovery 
protocol as described above. 
A 0.1% methanolic HCL solution was prepared by adding 0.1 ml of concentrated 
HCL to 90 ml methanol, mixing and then brought to a final volume of 100 ml. Hexane 
and N-butyl chloride solvents were used directly from stock bottles. These three 
solutions were used to release the analytes from the antibody following the washing 
procedure. Into each well was pipetted 250 uL of a releasing solution and allowed to 
stand for 30 min. Solvent from each well was collected and the contents of each 
designated row were placed in a labeled 16x125 mm screw cap tube for storage at 4 C 
until ready for analysis by GC/MS. 
Tubes containing the different releasing solutions were evaporated to dryness. 
To each tube, 40 uL of O-Bis (trimethylsilyl) trifluroacetamide (BSTFA) was added for 
derivatization of analytes. Each tube was then capped and incubated for 60 minutes at 
70° C. Derivatized samples were analyzed by GC/MS operating in the Selected Ion Mode 
(SIM). Ions chosen for A-9-THC were 386, 343 and 303 amu. The ions chosen for the 
internal standard of A-9-THC were 389 and 306. The ions chosen for A-9-THCA were 
371, 473 and 488 amu with 374 and 476 amu as the internal standard ions. 
Phase II 
Experimental Protocol 
Phase 2 of the research began with developing a protocol to immobilize drug 
specific A-9-THC monoclonal antibodies within a polystyrene cell culture flask. Two 
methods were chosen for binding of antibodies to the polystyrene surface; 1) passive 
absorption and 2) chemical linkage with glutaraldehyde. Two methods were chosen to 
first establish if one was more efficient to prepare and secondly which one would be 
more robust in performing the experiments. 
Passive Immobilization of Antibody 
Antibodies were mixed in an alkaline buffer and allowed to incubate in the 
extraction flask for absorption to take place prior to a blocking agent being added to the 
device: Devices were made fresh for each batch run. The protocol for the absorption 
experiment is given below: 
1. A 0.1 M buffer of sodium carbonate (Na2C03-H20), pH 11.3, was 
prepared by accurately weighting out 12.4 g and dissolving in 950 ml 
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Type III water. The pH was checked with an Accumet XL 25 (Fisher 
Scientific, Houston, TX) and the solution was brought to a final 
volume of 1000 ml. 
2. A 0.1 M buffer of sodium bicarbonate (NaCH03), pH 8.3, was 
prepared by accurately weighting out 8.4 g and dissolving in 950 ml 
Type III water. The pH was checked as above and the solution 
brought to a final volume of 1000 ml. 
3. 400 ml of the 0.1 M carbonate buffer was measured out and the pH 
was brought to 9.25 by addition of the sodium bicarbonate buffer up to 
a volume of 500 ml. 
4. 0.5 mg of A-9-THC antibody solution was added to 100 ml of the 
carbonate buffer for a concentration of 5 |ag antibody per ml of buffer, 
pH 9.25. 
5. 1 ml of the buffered antibody solution was placed in each extraction 
device and allowed to incubate overnight at room temperature. 
6. The following day each device was rinsed five times with phosphate 
buffered saline (PBS), pH 7.2. 
7. A 0.1M solution of 1-lysine was added to each device and allowed to 
incubate for 3 hrs at room temperature: L-lysine served as a blocking 
agent for any remaining active sites. 
8. The devices were then washed 5 times with PBS and allowed to air 
dry. 
9. 1 ml synthetic blood samples were spiked with 25 ng A-9-THC and 
added to 10 devices and incubated for 1 hr on a platform rotator 
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moving at 25 revolutions per min. 
Following the respective incubation periods, the devices were removed from the 
platform rotator and the contents poured into a biohazard waste container. Each device 
was then washed 5 times with sodium phosphate buffer (pH 7.2) to remove any 
remaining contaminants. The devices were allowed to drain for 30 min followed by 
addition of 2 ml of the releasing solvent. The devices were incubated in the releasing 
solvent for a period of 30 min. The 2 ml of releasing agent from each device was 
decanted into a clean 16 x 125 mm screw cap tube and labeled. Great care was taken not 
to collect any remaining traces of water or buffer from any devices during this step. 
Collected aliquots of solvent were dried at 60° C under vacuum. Forty (40) uL of 
BSTFA with 1% TMS was added to each tube. The tubes were then capped, vortexed 
and incubated at 70° C for 1 hr for derivatization prior to analysis by GC/MS. 
Glutar aldehyde Immobilization of Antibody 
The second method used glutaraldehyde as the linking molecule to chemically 
bind the antibody to the polystyrene surface. The protocol for gluteraldehyde bonding to 
a polystyrene surface is given below: 
1. A 0.1 M solution of sodium phosphate dibasic (Na2HP04), pH 9.5, 
was made by accurately weighting out 14.2 g and dissolving in 950 ml 
Type III water and brought to a final volume of 1000 ml. 
2. A 0.1 M solution of sodium phosphate monobasic (NaH2P04), pH 4.5, 
was made by accurately weighting out 12.0 g dissolving in 950 ml 
Type III water and brought to a final volume of 1000 ml. 
3. 450 ml of the monobasic buffer was measured and the pH adjusted to 
5.0 using the 0.1 M solution of sodium phosphate dibasic solution and 
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brought to a final volume of 500 ml. Final pH of 5.0 was checked 
using an Accumet 25 XL pH meter. 
4. 10 ml of a 25% glutaraldehyde solution was added to 40 ml of sodium 
phosphate buffer (pH 5.0) for 50 ml of a 5% glutaraldehyde solution. 
5. A sodium phosphate buffer at pH 8.0 was made by using the two 
buffer solutions above. 400 ml of the sodium dibasic buffer was 
measured out and brought to the proper pH as necessary using 0.1 M 
of sodium phosphate monobasic solution and brought to a final 
volume of 500 ml. 
6. 1 ml of the glutaraldehyde solution was pipetted into 10 devices and 
allowed to incubate at room temperature for a minimum of 4 hrs. 
7. Following incubation, each device was thoroughly washed with 
sodium phosphate buffer, pH 5.0. 
8. 0.5 mg of A-9-THC monoclonal antibody was added to 100 ml of a 
sodium phosphate buffer, pH 8.0, for a concentration of 5 ug antibody 
per ml of buffer. 
9. 1 ml of antibody solution was added to an extraction device and 
incubated at 37° C for a minimum of 3 hrs. 
10. Devices were allowed to cool to room temperature and washed with 
pH 8.0 sodium phosphate buffer 3 times. 
11. Each device was drained and washed twice with phosphate buffer, pH 
7.2, made from 0.1M solution of sodium phosphate monobasic and 
0.1M sodium phosphate dibasic followed by 2 washes with Type III 
water. 
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12. 1 ml synthetic blood samples were spiked with 25 ng A-9-THC. 
13. While vortexing, 1 ml of acetonitrile was added drop-wise using a 
variable pipettor. 
14. The samples were then centrifuged for 25 min at 3000 rpm and then 
the upper layer was transferred to a clean 15x125 mm screw cap tube. 
15. The acetonitrile layer was evaporated to approximately 250 mcl and 
then reconstituted with 1 ml of a 0.5% saline solution, vortexed and 
centrifuged at 3000 rpm for 25 min. 
16. The saline solution was transferred to prepared device and capped. 
17. The devices were incubated for 120 min on a platform rotator moving 
at 25 revolutions per min. 
The devices were treated as described under the "Passive Immobilization" 
section above. 
Monoclonal A-9-THC Antibodies 
Monoclonal drug antibodies produced against A-9- THC were purchased in 1 mg 
lots from BioDesign Co (Saco, ME). The purchase of a 1 mg lot of monoclonal 
antibodies was sufficient to make 200 extraction devices at a concentration of 5 ug of 
antibody per device. Description of the antibody purchased is as follows: 
1. Catalog # G82922M 
2. Description - monoclonal antibody to A-9-THC 
3. Clone D81 from Mouse ascites 
4. Immunogen - 8-THC-BSA 
5. Isotype IgGi 
6. Specificity to A-9-THC and metabolites 
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7. Buffer-PBSpH7.2 
8. Lot number 8D09407 
Extraction Device 
A Falcon® tissue flask (Thermo-Fisher Scientific, Houston, TX) with 12.5 cm2 
bottom surface area along with a canted neck and screw cap was chosen as the prototype 
container. The flask could be sealed with a non-vented screw cap and had a large enough 
orifice to easily add 1 to 2 ml of buffered sample and to pour off 2 to 3 ml of rinse 
solution and drug releasing solvent. The flasks have a flat bottom and were easy to stack 
for incubation on a platform rotator. 
Analyte Releasing Solvents 
The releasing solvents tested were an organic solvents and an acidic alcohol 
normally used in forensic laboratories in general extraction procedure for A-9-THC and 
A-9-THCA extraction purposes. The solvents chosen were hexane and 0.1% methanolic 
HC1. Each solvent was used individually to determine which was the most efficient. The 
releasing solution found optimal in Phase 1 of the study was tested first. Releasing 
solutions were collected in 16X125 mm borosilicate glass screw cap tubes and placed in 
a RapidVap® evaporator for drying under vacuum at 50°C. The dried extracts were 
reconstituted with 40 uL BSTFA plus 1% TMS, capped, vortexed and incubated for 60 
min at 70°C for derivatization. 
Gas Chromatograph and Mass Spectrometer Parameters 
The gas chromatograph injection port was set up in the splitless mode for 
injection of 2 uL of extracted samples using an autoinjector. The mass spectrometer was 
set up in the SIM mode to monitor 3 characteristic ions of each analyte and two ions for 
each internal standard. Secondary ion ratios were monitored to assure compliance within 
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the ± 20% criteria for confirmation. Gas chromatograph parameters were set as follows: 
1. GC was a Clarus 600 manufactured by Perkin Elmer, (Shelton, CT) 
2. Injection port temperature 250° C 
3. Initial oven temperature 120° C with an initial hold of 1.00 min 
4. Following 1 min hold, temperature was ramped 15° C/min to 320° C 
for a total run time of 14.33 min 
5. Column was a MS 5, 30 m in length with a 250 um diameter 
purchased from Perkin Elmer, (Shelton, CT) containing 5% phenyl 
and 95% polysiloxane 
Mass spectrometer parameters were set as follows: 
1. Mass Spectrometer was a Clarus 600 electron impact (EI+) quadrapole 
manufactured by Perkin Elmer, (Shelton, CT) 
2. Solvent delay from 0 to 10.62 min 
3. THC ions monitored were 303,386 and 387 (BSTFA+1 % TMS 
derivative) 
4. THCA ions monitored were 371, 473 and 488 (BSTFA+1% TMS 
derivative) 
5. A-9-THC-D3 and A-9-THCA-D3 ions monitored were 306, 389 and 
374, 476 respectfully. 
6. Window for THC was 10.63 to 11.63 min 
7. Window for THCA was 12.57 to 14.33 min 
8. Dwell times were 0.050 s for each ion 
9. Ion mode was EI+ 
10. Inter channel delay was 0.01 s for each ion monitored 
ELISA Testing of Glutaraldehyde Prepared Devices 
Extraction devices were prepared as described under the glutaraldehyde antibody 
immobilization section. One of the devices was treated as a negative with no analyte 
added. A-9-THC at concentrations of 10, 50, 100, 200, 500 and 1000 ng/ml A-9-THC 
were added to the remaining six devices. A total of five batch runs were performed. 
Following initial incubation and wash steps, 1 ml of conjugated THC-derivative 
was added to each device and incubated for 1 hr. The devices were washed six times 
with DI water following this second incubation to remove all traces of conjugated THC-
derivative. Next 1 ml of TMB color reagent was added to each device. Each device was 
mixed well by gentle swirling and allowed to incubate in the dark for 30 min. Stop 
reagent (1 N HC1) was added to each device following the 30 min incubation and the 
devices were thoroughly mixed again by gentle swirling to ensure reaction between TMB 
and conjugate was completely stopped. 
The contents from each device were transferred to labeled, 2 ml polystyrene 
cuvettes for reading absorbance values of each solution using a Lambda 35 UV/VIS 
spectrophotometer (Perkin Elmer, Shelton, CT) at 450 nm. 
Percent Yield Studies 
Percent yield of A-9-THC was determined by spiking ten, 1 ml aliquots of 
synthetic whole blood with 25 ng of the analyte and extracting these samples using 
devices prepared the day of analysis. A 25 ng/ml direct standard was used to determine 
the results of the extracted samples. A total of 5 experiments using 10 devices for each 
analyte were conducted on different days for a total of 50 experiments A-9-THC and A-9-
THCA. Percent yield data from experiments were compared using a Paired t test to 
determine if data demonstrated any significant statistical differences among the different 
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daily experiments. 
A second round of experiments to determine binding specificity was conducted 
by adding both A-9-THC and A-9-THCA to the same extraction device in order to 
determine if there was an appreciable effect on the recovery of THCA or both of the 
analytes. Both analytes were added to prepared extraction devices at equal 
concentrations of 10, 50, 100, and 150 ng/ml. Effect on binding specificity for THCA 
was determined by direct comparison of results from the respective analytes. The 
experiment was conducted five times. 
Linearity of Single Extracted Analytes 
One ml whole blood aliquots ranging from 3 to 50 ng/ml of each analyte were 
analyzed by the glutaraldehyde procedure and judged for acceptability. Criteria 
designated as acceptable linearity was a line having a correlation coefficient of r > 0.985. 
This procedure was conducted daily using five devices per run for a minimum of 50 
samples run over a 5 day period to test within run and day-to-day consistency of device 
preparation. 
Linearity of Extracted Analytes with Deuterated Internal Standards 
Deuterated internal standards (IS) were added to the next phase of the study. 
Whole blood samples were spiked at 25 ng/ml A-9-THC-D3 and 50 ng/ml A-9-THCA-D3 
with appropriate concentrations of A-9- THC and A-9-THCA to prepare a set of five 
calibrators ranging from 2.0 to 50 ng/ml for A-9-THC and 2.0 to 50 ng/ml for A-9-
THCA. These standards were prepared for the purpose of demonstrating linearity (r2 > 
0.985). 
Establishing limits of quantitation (LOQ) and limits of detection (LOD) for each 
analyte was accomplished by extracting 10 samples at designated concentrations. Ten 
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samples were spiked at a concentration of 0.5 ng/ml A-9-THC for LOD determination. 
Ten samples at a concentration of 1.0 ng/mlA-9-THC were extracted to determine LOQ. 
The same protocol was followed for A-9-THCA with concentrations of 2 and 5 ng/ml for 
LOD and LOQ, respectfully. 
Once linearity was established, quality control samples were prepared using 
standards from a separate lot of drug standards from the same vendor with concentrations 
that tested the low and high portions of the calibration curve; 5 and 30 ng/ml for A-9-
THC and 10 and 40 ng/ml for A-9-THCA. Acceptable criteria of controls were set at ± 
20% of expected concentration. 
Analysis of Postmortem Samples 
The final step in Phase 2 of the study was the analysis of postmortem blood 
samples secured from the Mississippi Crime Laboratory that had been previously 
analyzed by a reputable laboratory and extracting these samples using the new device. 
All experiments were conducted twice on different days to ensure the devices were 
consistent between runs. This experiment step consisted of two parts: 1) extraction of 
samples with known reported concentrations of one or both analytes, and 2) extraction 
of samples where concentrations of A-9-THC could not be reported due to interfering 
substances. Appropriate statistical tests were performed to evaluate the validity of the 
new extraction procedure where reported sample concentrations were known. Samples 
where values were not reported due to interfering substances were compared to the new 
extraction procedure to evaluate if interfering substances had been removed, thus 
allowing reporting of quantitative results. A-9-THCA was analyzed on all 30 samples 
following the same protocol. 
CHAPTER IV 
EXPERIMENTAL RESULTS 
Preparation of Drug and Internal Standards 
Drug standards of A-9-THC, A-9-THCA, A-9-THC-D3 and A-9-THCA-D3 were 
purchased from Cerilliant Corp. (Round Rock, TX). A-9-THC and A-9-THCA were 
purchased in concentrations of 1 mg/ml while the two deuterated internal standards were 
purchased in concentrations of 100 ug/ml. Stock standards of A-9-THC and A-9-THCA 
were made by diluting 1 ml of the respective analyte with 9 ml methanol for final 
concentrations of 100 |j,g/ml each. Stock standards for internal standards were 0.5 and 
1.0 mcg/ml for A-9-THC-D3 and A-9-THCA-D3 respectfully (Liu, et al., 1995). See 
Tables 1 and 2 for complete dilution protocols for making working solutions. 
Results of Phase 1 ELISA Experiments 
The first experiment was conducted by spiking separate 1.0 ml aliquots of 
synthetic blood in 16x125 mm screw cap tubes with 25 ng/ml of A-9-THC. As stated in 
the method protocol, 125 uL of spiked solution was placed in 56 designated wells and 
125 uL of negative blood was placed in first eight wells (see Figure 1) to establish the 
method worked in my laboratory as described by the manufacturer. Absorbance readings 
were measured for all wells using a Victor 3, 96 well plate-reader operating at 450 nm. 
Figure 1 demonstrates the cannabinoid ELISA kit worked as described by the 
manufacturer. The synthetic negative sample gave negative results as expected and the 
spiked samples at 25 ng/ml A-9-THC gave positive results. Analysis of the absorbance 
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Table 1 
Dilution protocol for Making Stock and Working Standards 
Stock Standards 
A-9-THC - 1 ml of a 1 mg/ml Standard + 9.0 ml MEOH = 100 mcg/ml: Stock Std 1 
1 ml of Stock Std 1 + 9.0 ml MEOH = 10 mcg/ml: Stock Std 2 
A-9-THC Working Standards 
1 ml of Stock Std 2 + 9.0 ml MEOH = 1 mcg/ml: Working Std 1 
0.4 ml Stock Std 2 + 9.6 ml MEOH = 0.4 mcg/ml: Working Std 2 
0.2 ml Stock Std 2 + 9.8 ml MEOH = 0.2 mcg/ml: Working Std 3 
0.1 ml Stock Std 2 + 9.9 ml MEOH = 0.1 mcg/ml: Working Std 4 
Calibrators 
50 uL Working Std 1 in 1 ml blood = 50 ng/ml A-9-THC 
50 uL Working Std 2 in 1 ml blood = 20 ng/ml A-9-THC 
50 uL Working Std 3 in 1 ml blood = 10 ng/ml A-9-THC 
30 uL Working Std 4 in 1 ml blood = 3 ng/ml A-9-THC 
Stock Standards 
A-9-THCA - 1 ml of a 1 mg/ml Standard + 9.0 ml MEOH = 100 mcg/ml: Stock Std 3 
1 ml of Stock Std 3 + 9.0 ml MEOH = 10 mcg/ml: Stock Std 4 
A-9-THCA Working Standards 
1 ml Stock Std 2 + 9.0 ml MEOH = 1 ng/ml: Working Std 5 
0.4 ml Stock Std 2 + 9.6 ml MEOH = 0.4 ug/ml: Working Std 6 
0.2 ml Stock Std 2 + 9.8 ml MEOH = 0.2 ng/ml: Working Std 7 
0.1 ml Stock Std 2 + 9.9 ml MEOH = 0.1 ng/ml: Working Std 8 
Calibrators 
50 uL Working Std 5 in 1 ml blood = 50 ng/ml A-9-THCA 
50 nL Working Std 6 in 1 ml blood = 20 ng/ml A-9-THCA 
50 nL Working Std 7 in 1 ml blood = 10 ng/ml A-9-THCA 
50 nL Working Std 8 in 1 ml blood = 5 ng/ml A-9-THCA 
Table 1: Calibrators of A-9-THC and A-9-THCA were made by adding amounts shown 
in the table to 1 ml aliquots of postmortem blood. Calibrators were made new for each 
run of 10 samples from the Mississippi Crime Laboratory. 
Table 2 
Dilution Protocol for Making Internal Standard Spiking Solutions 
Stock Standard A-9-THC-D3 
1 ml of 100 ug A-9-THC-D3 + 9 ml MEOH = 10 ug/ml: Stock Solution 
1 ml of 10 i^g/ml A-9-THC-D3 + 9 ml MEOH = 1 ug/ml: Working Solution 
25 uL of Working Solution to 1 ml sample = 25 ng/ml A-9-THC-D3 
Stock Standard A-9-THCA-D3 
1 ml of 100 A-9-THCA-D3 + 9 ml MEOH = 10 ug/ml: Stock Solution 
1 ml of 10 mcg/ml A-9-THCA-D3 + 4 ml MEOH = 2 mcg/ml: Working Solution 
25 uL of Working Solution to 1 ml sample = 50 ng/ml A-9-THCA-D3 
Table 2: 25 uL of each internal standard is added to all calibrators, controls and samples 
to be used for quantitation curves and determination of control and sample values. 
Figure 1 
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Figure 1: Display from Victor 3 showing the results from an ELISA run. The first row 
in red is a negative whole blood sample. The blue samples are positive results from 
whole blood samples spiked with 25 ng/ml A-9-THC. The figure demonstrates the 
ELISA kit worked as described by the manufacturer in my laboratory. 
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Figure2: Display shows all four analytes added to separate 1 ml whole blood samples 
a concentration of 25 ng/ml and run in duplicate. The figure demonstrates that all 
analytes are bound by the antibodies and retained including the deuterated internal 
standards A-9-THC-D3 and A-9-THCA-D3. 
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values for the eight negative readings gave a mean of 1.824 with a standards deviation of 
0.231. The positive samples resulted in a mean of 0.224 and a standard deviation of 
0.023. The values achieved indicate that the pipetting was precise and the automated 
washer worked as expected in removing all unbound traces of the conjugated THC-
derivative. The results also demonstrated that A-9-THC remained attached to the 
antibody during the washing procedure and was not released. 
Results of Second ELISA Experiment 
Synthetic blood aliquots spiked individually with 25 ng of all four analytes were 
pipetted into 16 different wells and results shown in Table 3 demonstrated that the 
antibody cross-reacted with all four analytes tested with basically equal affinity given the 
closely related absorbance values. The results also indicate that the three other analytes 
of interest were held by the antibody during the washing steps and not released from the 
antibody. 
Results of Releasing Agent Experiment 
Synthetic blood aliquots of 1 ml were spiked with 25 ng A-9-THC and carried 
through the ELISA protocol as described for the recovery experiments. The appropriate 
volume (125 uL) of a selected solution was added to designated wells and allowed to 
incubate for the times stated above. The 0.1% acidic methanol resulted in the best 
recovery of A-9-THC averaging 22%. Hexane was the second best with an average 
recovery of 15%. N-butyl chloride reacted with the polystyrene resulting in no recovery 
of analytes. The 25 ng/ml spiked solutions did have analyte present from both releasing 
agents as shown in Figure 3. Two major ions were present with no interfering peaks 
present. 
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Table 3 
EUSA ASSAY on A-9-THC; A-9-THCA; A-THC-D3; A-9-THCA-D3 
Plate 
1 
Repeat Erci time Start temp. Erai temp. 8arC«fe 
11:07:14 PM 24.5 24.5 WA 
Absorbance @ 450 (1,0s) (A) 
^1.000 
Avg. Abs 
0.20D 
0.200 
0211 
0.208 
0.235 
0.206 
0.204 
0.207 
0.209 
0.224 
0.209 
0.209 
0.204 
0.22S 
0.207 
0.205 
0537 
0.215 
<£"••"• .K'~ 
. • - : • 
••>•':. •>:.•<•'. 
. -• : :>K :>^ 
. . ' . . • • ' • : • 
>... .:• ..•>. 
g; :f $ 
0.203 
0.220 
0.199 
0.1S7 
0.227 
0.212 
0.204 
0.203 
0.208 
0.200 :: 
0.197 ';! 
0.234 :. 
0.233 : : 
0.207 I; 
0.205 =! 
0200 :. 
0.204 !-; 
0.210 
: ; j ; : : ; : : 0.422 
: ; i ! ; . | : - . ' ! 0.427 
; ! : ; ; ; : j ; : = 0.451 
: ; : - : j : : ; '[ 0.514 
X ;!: ; ; : : 0.488 
j l : : : ; : i : i j : 0.SS8 
0.497 
0.419 
0.444 
0.522 
0.436 
0.498 
0.409 
0.420 
0.414 
0.445 
g ? g ^ ! : ^ 
:£W^i*§£ 
5Sj™^:|§i 
SSSfeSSSSI 
iilli 
• 
0.249 
0.255 
0.261 
0.259 
0.277 
0.257 
0.266 
0.267 
0.261 
0.254 
0.254 
0.260 
0.281 
0.263 
0.262 
0.258 
0.267 
0.260 
0.198 
0.1S7 
0.207 
0.204 
0.230 
0.202 
0.201 
0.203 
0.220 ;•::;; 
0.208 :;:;:: 
0.204 :;;.-:: 
0.199 !:;:'•: 
0.222 ;;;:;• 
0.203 ; : . ; i : : 
0.201 •;:;••: 
0.231 ;-|:;i 
:;•;:;. 0.200 
\--\::.-: 0.213 
;•;•:•• 0.20s 
: : i ; . ' i : 0.193 
:•:••:• 0.223 
.;;••!:; 0.209 
::;•::••; 0.200 
: | i ' : : . : . 0.200 
0.196 : 
0.193 •; 
0.229 : 
8.227 : 
0.212 : 
0.201 : 
0.197 ; 
0.202 : 
:j:j:;:j:j: 
; : ; • : • ' : ; • : • : ; 
I 0.412 
: 0.416 
• 0.441 
:
 0.503 
| 0.487 
: 0.587 
: 0.574 
i 0.472 
0.409 •.:: : 
0.434 : ::: ::- : 
0513 : . : ' : ; : 
0.426 •;:••.: 
0.482 -::• :: 
0.499
 : : : ; : ; r 
0.418 •.;:•:••: 
0.403 : : : i : : : 
:. - : . 0.249 
:;; . ; : ; 0.256 
|: :•':, 0.262 
::::':.:- 0.259 
••::;:. 0.279 
•.:'.:•:: 0.257 
:::::-:: Q.267 
.-•:;. 0266 
0.254 
0.254 
0.259 
0.260 
0.263 
0.261 
0.258 
0.268 
Avg. Abs 0.205 0.211 0.205 0.207 0.487 0.448 0.262 0.260 
Table 3: Absorbance values from ELISA analysis of all four analytes of interest at 25 
ng/ml. From left to right the analytes are A-9-THC, A-9-THCA, A-9-THCA-D3 and A-9-
THC-D3. All have consistent readings with the exception of A-9-THCA-D3 which 
shows absorbance values approximately two times the other three analytes. 
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The samples collected of each solution from the designated row of wells 
representing a negative sample, were evaporated to dryness with air in a 60 C water bath. 
To each tube 40 uL of O-Bis (trimethylsilyl) trifluroacetamide (BSTFA) was added for 
derivatization. Each negative sample tube was analyzed by GC/MS in the same manner 
as those containing analyte. Figure 3 shows that no A-9-THC was found in the tubes 
representing the negative sample. This finding indicates that the pipettor, saline solution, 
derivatization solvent and ELISA plate and reagents were not contaminated with A-9-
THC. 
Figure 4 shows an example of A-9-THC that was extracted using the ELISA 
plates. The three ions were all present and met ratio criteria for confirmation. The 
recovery of A-9-THC using these plates is poor as noted by the high baseline. A-9-
THCA recovery was also poor using the ELISA plates. The three ions of interest did 
meet the confirmation criteria. 
Acceptable calibration curves could not be demonstrated using the ELISA plates 
for either A-9-THC or A-9-THCA. Poor recovery of analytes using the plates would 
explain the inability to recover analytes with a degree of precision. Internal standards of 
A-9-THC-D3 or A-9-THCA-D3 were not used in any of the extractions procedures from 
the ELISA plates or to see if an acceptable calibration curve could be obtained given the 
ELISA plates were not the device of choice for final experiments. 
Figure 3 
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Figure 3: Negative sample of A-9-THC showing that the three ion of interest are not 
present and would not meet ratio criteria for being considered acceptable. The figure also 
shows none of the items used to prepare the sample were contaminated with A-9-THC. 
Figure 4 
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Figure 4: Shows the three ions monitored for A-9-THC by GC/MS analysis. The figure 
represents a 25 ng/ml sample that was extracted from an ELISA plate using 0.1% acidic 
methanol. Recovery is poor as demonstrated by the low baseline levels. Ions peaks 
pictured for A-9-THC are 386, 303 and 387 from top to bottom. 
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Falcon® Cell Culture Flask Chosen As Extraction Device 
A 25 ml Falcon® cell culture flask was chosen as the device for binding of 
antibodies and extraction of samples (see Figure 5). The device was easy to handle and 
had several qualities that may it a good choice for initial experiments. 
Sample Treatment with Acetonitrile 
As described under the Methods and Material chapter, postmortem samples had to 
be treated with acetonitrile prior to use with the extraction devices. Figure 6 shows the 
difference in sample appearance following the acetonitrile treatment. A-9-THC or A-9-
THCA could not be extracted from postmortem samples using untreated blood samples. 
Results of Passive Immobilization of Antibodies 
The passive method for immobilizing the antibodies was not deemed successful 
to the point of continuing experiments using this method. Recovery of A-9-THC was 
poor only averaging 20% with a range of 0 to 32%. There was no recovery of analyte in 
some 40% of the experiments conducted. 
One of the problems was the 1-lysine used as a blocking agent. The acidic 
methanol releasing solution would extract this compound leaving a white film of 1-lysine 
in the tubes following evaporation. The 1-lysine would dissolve in the BSTFA leaving 
the BSTFA solution white and opaque. This created chromatographic problems requiring 
cleaning or changing of the glass injection inserts following approximately every 15 
injections. Removing the step of adding the lysine reduced the chromatographic 
problems but did not improve recovery of analyte using the acidic methanol or hexane. 
Use of hexane as the releasing solution did not appear to remove the lysine from 
the extraction devices given there was no white film visible in evaporated tubes and did 
not result in any chromatographic problems or required cleaning of injection inserts. 
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Figure 5 
Figure 5: Photographs of 25 ml Falcon® cell culture flasks used as extraction 
devices. The flasks have 12.5 cm2 surface area on the bottom surface which 
was adequate for chemically binding 5 meg of antibody. 
Figure 6 
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Figure 6: Tube on the left is a postmortem sample prior to any 
treatment with acetonitrile. The middle tube represents the sample 
after treatment and centrifugation and decanting into a clean tube. 
The tube on the right is the final sample following evaporation of the 
acetonitrile and addition of 1 ml buffered saline. 
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However, the recovery of analyte did not improve as compared to the acidic methanol 
and many devices showed no recovery of analytes. 
Given that these two releasing solutions both demonstrated poor if any recovery 
of analyte using this method of immobilization of antibody, lead to two conclusions as to 
why this method did not work. One was that there was insufficient antibody bound to the 
extraction devices and/or that the antibody was removed during the washing steps. This 
experimental protocol was abandoned with no further attempts to improve its 
performance. 
Results ofELISA Testing ofGlutaraldehyde Bound Antibody 
Five experiments were conducted where flasks treated with glutaraldehyde for 
antibody immobilization had 1 ml samples at concentrations of A-9-THC of 0,10, 50, 
100,200, 500 and 1000 ng added and allowed to incubate for 1 hour. The flasks were 
washed as described in the method protocol and dried. ELISA reagents were then used to 
estimate binding capacity of the flasks for A-9-THC as described in the ELISA method 
(see Figure 7). All experiments showed an inverse relationship of absorbance to 
concentration as expected. A concentration > 200 ng A-9-THC approached the limit of 
the flask to show any further binding capacity (see Figures 8, 9,10,11 and 12). Average 
absorbance values from the five experiments were 3.1323 for 0 ng, 2.5765 for 10 ng, 
1.8673 for 50 ng, 0.6063 for 100 ng, 0.2172 for 200 ng, 0.0229 for 500 ng and 0.0015 for 
1000 ng (see Table 4 and Figure 13). 
Percent Yield Results with Glutaraldehyde Immobilized Antibodies 
Ten flasks were then carried through the antibody attachment protocol on five 
different days for % yield studies. Each sample was spiked with 25 ng A-9-THC and 
carried through the extraction process. The average yield for A-9-THC was 54% with a 
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range of 50 to 61%. The same study was performed using A-9-THCA resulting in an 
average % yield of 47% with a range of 37 to 52% (see Table 5 and Tables 6-15). 
Paired / test statistical analyses were run on the percent yield results for A-9-THC 
to see if there was a significant difference between the groups. Each group was 
compared statistically to all other groups during these analyses. There was a statistically 
significant difference found between all the groups demonstrating the difference did not 
occur by chance. 
The same statistical analyses were conducted on the A-9-THCA results for the 
five experiments. The statistical analyses showed a significant difference between each 
group. Again these analyses show that the device is working as designed for both A-9-
THC and A-9-THCA and the production from day-to-day is consistent. 
Experiments were conducted as above when adding both A-9-THCand A-9-
THCA at 25 ng each to determine ant difference in recovery when both analytes were 
present. There was no significant difference in recovery at this concentration of analytes. 
Next devices were made according to the glutaraldehyde protocol and both analytes were 
added to a single device at increasing concentrations. The concentrations were 10,20, 
40, 60, 80, 100 and 150 ng/ml. Recovery of both analytes was consistent from 10 to 60 
ng/ml. The recovery of A-9-THCA began to fall when the concentration of A-9-THC 
began to approach 80 ng (see Figure 14). Concentrations of A-9-THC above 80 ng/ml 
showed continued recovery while the A-9-THCA recovery fell at each rise in 
concentration A-9-THC. 
Figure 7 
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Figure 7: Flasks treated with glutaraldehyde to immobilize monoclonal THC antibodies 
subjected to ELISA reagents to determine binding capacity of A-9-THC. Concentrations 
range from 0 to 1000 ng/ml. Note that the color diminishes as the A-9-THC 
concentration rises. The 1000 ng/ml flask shows no color indicating no antibody binding 
sites were available for THC-derivative to bind. 
Figure 8 
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Experiment 1 of Binding Capacity of Extraction Device 
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Figure 8: Bar graph shows the absorbance values from flasks treated with glutaraldehyde 
for immobilization of antibodies and subjected to ELISA reagents to determine binding 
capacity of A-9-THC. 
Figure 9 
47 
Experiment 2 of Binding Capacity of Extraction Device 
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Figure 9: Bar graph shows the absorbance values from second experiment of flasks 
treated with glutaraldehyde for immobilization of antibodies and subjected to ELISA 
reagents to determine binding capacity of A-9-THC. 
Figure 10 
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Experiment 3 of Binding Capacity of Extraction Device 
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Figure 10: Bar graph shows the absorbance values from third experiment of flasks 
treated with glutaraldehyde for immobilization of antibodies and subjected to ELISA 
reagents to determine binding capacity of A-9-THC. 
Figure 11 
Experiment 4 of Binding Capacity of Extraction Device 
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Figure 11: Bar graph shows the absorbance values from fourth experiment of flasks 
treated with glutaraldehyde for immobilization of antibodies and subjected to ELISA 
reagents to determine binding capacity of A-9-THC. 
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Figure 12 
Experiment 5 of Binding Capacity of Extraction Device 
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Figure 12: Bar graph shows the absorbance values from fifth experiment of flasks treated 
with glutaraldehyde for immobilization of antibodies and subjected to ELISA reagents to 
determine binding capacity of A-9-THC. 
Table 4 
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Mean 
Abs. 
Values 
0.0 ng/ml 
3.1321 
3.4588 
3.1855 
2.8851 
3.0001 
3.1323 
10 ng/ml 
2.1056 
2.8121 
2.6996 
2.4439 
2.8211 
2.5765 
50 ng/ml 
1.9555 
1.8663 
1.7063 
1.8850 
1.9232 
1.8673 
100 ng/ml 
0.6201 
0.7452 
0.5332 
0.5002 
0.5330 
0.6063 
200 ng/ml 
0.2860 
0.2956 
0.1569 
0.1877 
0.1596 
0.2172 
500 ng/ml 
0.0145 
0.0289 
0.0097 
0.0180 
0.0433 
0.0229 
1000 
ng/ml 
0.0023 
0.0010 
0.0005 
0.0013 
0.0023 
0.0015 
Table 4: Original absorbance values from five experiments of flasks treated with ELISA 
reagents in determining capacity of A-9-THC to be bound by extraction devices. 
Figure 13 
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Figure 13: Error bars show variations of absorbance readings from binding capacity 
experiments using the extraction flasks. As the concentration of A-9-THC increases, 
the variation becomes smaller as more binding sites are unavailable for binding the 
THC derivative that generates the color change. 
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Table 5 
PERCENT YIELD DATA for THC EXPERIMENTS 
EXP1 
EXP 2 
EXP 3 
EXP 4 
EXP 5 
Mean 
ng/ml 
15.3 
13.1 
13.0 
12.6 
13.8 
Avg. % Yield 
% 
Yield 
0.61 
0.52 
0.52 
0.50 
0.55 
0.54 
PERCENT YIELD DATA for THCA EXPERIMENTS 
EXP1 
EXP 2 
EXP 3 
EXP 4 
EXP 5 
Mean 
ng/ml 
12.9 
9.3 
12.6 
11.5 
12.8 
Avg. % Yield 
% 
Yield 
0.52 
0.37 
0.50 
0.46 
0.51 
0.47 
Table 5: Shows the average percent recovery in ng/ml of A-9-THC and A-9-THCA 
when compared to a direct standard at a concentration of 25 ng/ml. Data is from 
five experiments of 10 samples individually spiked and carried through the 
glutaraldehyde antibody bound procedure. 
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Table 6 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\072707A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THC 
Printed: Fri Jul 27 10:48:51 2007 
Sample Name: 072707A1 
THC 
Sample Qualifiers Cone. 
RT P/F ng/ml 
Sample ID: 25 ng/ml CAL1 
11.13 Pass 25 
Sample Name: 072707A2 
THC 
Sample ID: Spike 1 
11.14 Pass 14.5 
Sample Name: 072707A3 
THC 
Sample ID: Spike 2 
11.13 Pass 17.3 
Sample Name: 072707A4 
THC 
Sample ID: Spike 3 
11.13 Pass 13.4 
Sample Name: 072707A5 
THC 
Sample ID: Spike 4 
11.14 Pass 15.9 
Sample Name: 072707A6 
THC 
Sample ID: Spike 5 
11.13 Pass 18.2 
Sample Name: 072707A7 
THC 
Sample ID: Spike 6 
11.13 Pass 14.9 
Sample Name: 072707A8 
THC 
Sample ID: Spike 7 
11.13 Pass 13.7 
Sample Name: 072707A9 
THC 
Sample ID: Spike 8 
11.13 Pass 18.8 
Sample Name: 072707A10 
THC 
Sample ID: Spike 9 
11.13 Pass 11.6 
Sample Name: 072707A11 
THC 
Sample ID: Spike 10 
11.13 Pass 15.1 
Table 6: Experiment 1 of percent yield studies for A-9-THC. The first injection was a 
direct 25 ng/ml standard. The 10 subsequent injections were compared to the direct 
standard for determination of A-9-THC yield from extraction devices. 
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Table 7 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\072807A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THC 
Printed: Sat Jul 28 13:18:50 2007 
Sample Qualifiers Cone. 
RT P/F ng/ml 
Sample Name: 072807A1 Sample ID: 25 ng/ml CAL2 
THC 11.13 Pass 25 
Sample Name: 072807A2 Sample ID: Spike 11 
THC 11.14 Pass 15.4 
Sample Name: 072807A3 Sample ID: Spike 12 
THC 11.13 Pass 12.9 
Sample Name: 072807A4 Sample ID: Spike 13 
THC 11.13 Pass 15.0 
Sample Name: 072807A5 Sample ID: Spike 14 
THC 11.14 Pass 14.7 
Sample Name: 072807A6 Sample ID: Spike 15 
THC 11.13 Pass 16.1 
Sample Name: 072807A7 Sample ID: Spike 16 
THC 11.13 Pass 15.6 
Sample Name: 072807A8 Sample ID: Spike 17 
THC 11.13 Pass 12.4 
Sample Name: 072807A9 Sample ID: Spike 18 
THC 11.13 Pass 12.7 
Sample Name: 072807A10 Sample ID: Spike 19 
THC 11.13 Pass 15.2 
Sample Name: 072807A11 Sample ID: Spike 20 
THC 11.13 Pass 17.1 
Table 7: Experiment 2 of percent yield studies for A-9-THC. The first injection was a 
direct 25 ng/ml standard. The 10 subsequent injections were compared to the direct 
standard for determination of A-9-THC yield from extraction devices. 
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Table 8 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\073007A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THC 
Printed: Tue Jul 30 19:32:30 2007 
Sample Name: 073007A1 
THC 
Sample Qualifiers Cone. 
RT P/F ng/ml 
Sample ID: 25 ng/ml CAL3 
11.13 Pass 25 
Sample Name: 073007A2 
THC 
Sample ID: Spike 21 
11.14 Pass 15.0 
Sample Name: 073007A3 
THC 
Sample ID: Spike 22 
11.13 Pass 15.3 
Sample Name: 073007A4 
THC 
Sample ID: Spike 23 
11.13 Pass 12.1 
Sample Name: 073007A5 
THC 
Sample ID: Spike 24 
11.14 Pass 12.9 
Sample Name: 073007A6 
THC 
Sample ID: Spike 25 
11.13 Pass 17.2 
Sample Name: 073007A7 
THC 
Sample ID: Spike 26 
11.13 Pass 11.0 
Sample Name: 073007A8 
THC 
Sample ID: Spike 27 
11.13 Pass 15.8 
Sample Name: 073007A9 
THC 
Sample ID: Spike 28 
11.13 Pass 13.0 
Sample Name: 073007A10 
THC 
Sample ID: Spike 29 
11.13 Pass 14.3 
Sample Name: 073007A11 
THC 
Sample ID: Spike 30 
11.13 Pass 17.5 
Table 8: Experiment 3 of percent yield studies for A-9-THC. The first injection was a 
direct 25 ng/ml standard. The 10 subsequent injections were compared to the direct 
standard for determination of A-9-THC yield from extraction devices. 
57 
Table 9 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\073107A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THC 
Printed: Tue Jul 31 16:12:33 2007 
Sample Name: 073107A1 
THC 
Sample Qualifiers Cone. 
RT P/F ng/ml 
Sample ID: 25 ng/ml CAL 4 
11.13 Pass 25 
Sample Name: 073107A2 
THC 
Sample ID: Spike 31 
11.14 Pass 12.6 
Sample Name: 073107A3 
THC 
Sample ID: Spike 32 
11.13 Pass 11.8 
Sample Name: 073107A4 
THC 
Sample ID: Spike 33 
11.13 Pass 13.3 
Sample Name: 073107A5 
THC 
Sample ID: Spike 34 
11.14 Pass 12.0 
Sample Name: 073107A6 
THC 
Sample ID: Spike 35 
11.13 Pass 15.9 
Sample Name: 073107A7 
THC 
Sample ID: Spike 36 
11.13 Pass 14.1 
Sample Name: 073107A8 
THC 
Sample ID: Spike 37 
11.13 Pass 12.6 
Sample Name: 073107A9 
THC 
Sample ID: Spike 38 
11.13 Pass 13.4 
Sample Name: 073107A10 
THC 
Sample ID: Spike 39 
11.13 Pass 11.6 
Sample Name: 073107A11 
THC 
Sample ID: Spike 40 
11.13 Pass 14.2 
Table 9: Experiment 4 of percent yield studies for A-9-THC. The first injection was a 
direct 25 ng/ml standard. The 10 subsequent injections were compared to the direct 
standard for determination of A-9-THC yield from extraction devices. 
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Table 10 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\080107A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THC 
Printed: Wed Aug 01 17:12:49 2007 
Sample Qualifiers Cone. 
RT P/F ng/ml 
Sample Name:080107Al Sample ID: 25 ng/ml CAL 5 
THC 11.13 Pass 25 
Sample Name: 080107A2 Sample ID: Spike 41 
THC 11.14 Pass 16.1 
Sample Name: 080107A3 Sample ID: Spike 42 
THC 11.13 Pass 12.0 
Sample Name: 080107A4 Sample ID: Spike 43 
THC 11.13 Pass 13.6 
Sample Name: 080107A5 Sample ID: Spike 44 
THC 11.14 Pass 13.6 
Sample Name: 080107A6 Sample ID: Spike 45 
THC 11.13 Pass 13.2 
Sample Name: 080107A7 Sample ID: Spike 46 
THC 11.13 Pass 14.1 
Sample Name: 080107A8 Sample ID: Spike 47 
THC 11.13 Pass 16.2 
Sample Name: 080107A9 Sample ID: Spike 48 
THC 11.13 Pass 13.7 
Sample Name: 080107A10 Sample ID: Spike 49 
THC 11.13 Pass 14.2 
Sample Name: 080107A11 Sample ID: Spike 50 
THC 11.13 Pass 16.3 
Table 10: Experiment 5 of percent yield studies for A-9-THC. The first injection was a 
direct 25 ng/ml standard. The 10 subsequent injections were compared to the direct 
standard for determination of A-9-THC yield from extraction devices. 
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Table 11 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\072707A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSCYMethDB\THCA 
Printed: Fri Jul 27 10:48:51 2007 
Sample Name:072707A12 
THCA 
Sample Qualifiers Cone. 
RT P/F ng/ml 
Sample ID: 25 ng/ml CAL 1 
13.07 Pass 25 
Sample Name: 072707A13 
THCA 
Sample ID: Spike 1 
13.08 Pass 12.2 
Sample Name: 072707A14 
THCA 
Sample ID: Spike 2 
13.07 Pass 10.5 
Sample Name: 072707A15 
THCA 
Sample ID: Spike 3 
13.07 Pass 11.7 
Sample Name: 072707A16 
THCA 
Sample ID: Spike 4 
13.07 Pass 12.0 
Sample Name: 072707A17 
THCA 
Sample ID: Spike 5 
13.07 Pass 10.3 
Sample Name: 072707A18 
THCA 
Sample ID: Spike 6 
13.07 Pass 11.3 
Sample Name: 072707A19 
THCA 
Sample ID: Spike 7 
13.07 Pass 14.0 
Sample Name: 072707A20 
THCA 
Sample ID: Spike 8 
13.07 Pass 14.6 
Sample Name: 072707A21 
THCA 
Sample ID: Spike 9 
13.07 Pass 10.2 
Sample Name: 072707A22 
THCA 
Sample ID: Spike 10 
13.07 Pass 12.9 
Table 11: Experiment 1 of percent yield studies for A-9-THCA. The first injection was a 
direct 25 ng/ml standard. The 10 subsequent injections were compared to the direct 
standard for determination of A-9-THCA yield from extraction devices. 
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Table 12 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\072807A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Sat Jul 28 13:18:50 2007 
Sample Name:072807A12 
THCA 
Sample Qualifiers Cone. 
RT P/F ng/ml 
Sample ID: 25 ng/ml CAL 2 
13.07 Pass 25 
Sample Name: 072807A13 
THCA 
Sample ID: Spike 11 
13.07 Pass 15.4 
Sample Name: 072807A14 
THCA 
Sample ID: Spike 12 
13.08 Pass 12.9 
Sample Name: 072807A15 
THCA 
Sample ID: Spike 13 
13.07 Pass 15.0 
Sample Name: 072807A16 
THCA 
Sample ID: Spike 14 
13.07 Pass 14.7 
Sample Name: 072807A17 
THCA 
Sample ID: Spike 15 
13.07 Pass 16.1 
Sample Name: 072807A18 
THCA 
Sample ID: Spike 16 
13.07 Pass 15.6 
Sample Name: 072807A19 
THCA 
Sample ID: Spike 17 
13.08 Pass 12.4 
Sample Name: 072807A20 
THCA 
Sample ID: Spike 18 
13.07 Pass 12.7 
Sample Name: 072807A21 
THCA 
Sample ID: Spike 19 
13.07 Pass 15.2 
Sample Name: 072807A22 
THCA 
Sample ID: Spike 20 
13.07 Pass 17.1 
Table 12: Experiment 2 of percent yield studies for A-9-THCA. The first injection was a 
direct 25 ng/ml standard. The 10 subsequent injections were compared to the direct 
standard for determination of A-9-THCA yield from extraction devices. 
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Table 13 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\073007A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Mon Jul 30 16:12:33 2007 
Sample Name: 073007A12 
THCA 
Sample Qualifiers Cone. 
RT P/F ng/ml 
Sample ID: 25 ng/ml CAL 3 
13.07 Pass 25 
Sample Name: 073007A13 
THCA 
Sample ID: Spike 21 
13.07 Pass 13.6 
Sample Name: 073007A14 
THCA 
Sample ID: Spike 22 
13.08 Pass 14.0 
Sample Name: 073007A15 
THCA 
Sample ID: Spike 23 
13.07 Pass 13.7 
Sample Name: 073007A16 
THCA 
Sample ID: Spike 24 
13.07 Pass 12.6 
Sample Name: 073007A17 
THCA 
Sample ID: Spike 25 
13.08 Pass 13.1 
Sample Name: 073007A18 
THCA 
Sample ID: Spike 26 
13.08 Pass 14.9 
Sample Name: 073007A19 
THCA 
Sample ID: Spike 27 
13.08 Pass 15.2 
Sample Name: 073007A20 
THCA 
Sample ID: Spike 28 
13.07 Pass 13.4 
Sample Name: 073007A21 
THCA 
Sample ID: Spike 29 
13.07 Pass 10.3 
Sample Name: 073007A22 
THCA 
Sample ID: Spike 30 
13.07 Pass 11.6 
Table 13: Experiment 3 of percent yield studies for A-9-THCA. The first injection was a 
direct 25 ng/ml standard. The 10 subsequent injections were compared to the direct 
standard for determination of A-9-THCA yield from extraction devices. 
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Table 14 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\073107A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Tue Jul 31 19:32:303 2007 
Sample Name: 073107A12 
THCA 
Sample Qualifiers Cone. 
RT P/F ng/ml 
Sample ID: 25 ng/ml CAL 4 
13.07 Pass 25 
Sample Name: 073107A13 
THCA 
Sample ID: Spike 31 
13.08 Pass 10.6 
Sample Name: 073107A14 
THCA 
Sample ID: Spike 32 
13.07 Pass 11.4 
Sample Name: 073107A15 
THCA 
Sample ID: Spike 33 
13.07 Pass 11.5 
Sample Name: 073107A16 
THCA 
Sample ID: Spike 34 
13.07 Pass 12.0 
Sample Name: 073107A17 
THCA 
Sample ID: Spike 35 
13.07 Pass 13.2 
Sample Name: 073107A18 
THCA 
Sample ID: Spike 36 
13.08 Pass 11.9 
Sample Name: 073107A19 
THCA 
Sample ID: Spike 37 
13.07 Pass 10.6 
Sample Name: 073107A20 
THCA 
Sample ID: Spike 38 
13.07 Pass 13.0 
Sample Name: 073107A21 
THCA 
Sample ID: Spike 39 
13.07 Pass 11.2 
Sample Name: 073107A22 
THCA 
Sample ID: Spike 40 
13.08 Pass 11.5 
Table 14: Experiment 4 of percent yield studies for A-9-THCA. The first injection was a 
direct 25 ng/ml standard. The 10 subsequent injections were compared to the direct 
standard for determination of A-9-THCA yield from extraction devices. 
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Table 15 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\080107A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Wed Aug 0117:12:49 2007 
Sample Name:080107Al 
THCA 
Sample Qualifiers Cone. 
RT P/F ng/ml 
Sample ID: 25 ng/ml CAL 5 
13.07 Pass 25 
Sample Name: 080107A2 
THCA 
Sample ID: Spike 41 
13.07 Pass 12.4 
Sample Name: 080107A3 
THCA 
Sample ID: Spike 42 
13.08 Pass 11.7 
Sample Name: 080107A4 
THCA 
Sample ID: Spike 43 
13.11 Pass 11.9 
Sample Name: 080107A5 
THCA 
Sample ID: Spike 44 
13.07 Pass 13.3 
Sample Name: 080107A6 
THCA 
Sample ID: Spike 45 
13.08 Pass 13.2 
Sample Name: 080107A7 
THCA 
Sample ID: Spike 46 
13.07 Pass 12.1 
Sample Name: 080107A8 
THCA 
Sample ID: Spike 47 
13.07 Pass 13.1 
Sample Name: 080107A9 
THCA 
Sample ID: Spike 48 
13.08 Pass 11.0 
Sample Name: 080107A10 
THCA 
Sample ID: Spike 49 
13.07 Pass 13.2 
Sample Name: 080107A11 
THCA 
Sample ID: Spike 50 
13.08 Pass 13.8 
Table 15: Experiment 5 of percent yield studies for A-9-THCA. The first injection was a 
direct 25 ng/ml standard. The 10 subsequent injections were compared to the direct 
standard for determination of A-9-THC A yield from extraction devices. 
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Figure 14 
Effect of Incresed THC Concentration on Binding 
Capacity for THCA 
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Figure 14: Demonstrates the effect of increasing the concentration of A-9-THC on the 
binding capacity of A-9-THCA by the glutaraldehyde bound antibody in an extraction 
device. The antibody is monoclonal for A-9-THC and has a greater affinity for that 
analyte over A-9-THCA. 
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Linearity of Individual Extracted Analytes 
One ml of negative synthetic blood was added to one treated flask as a negative 
sample and 1 ml aliquots of spiked synthetic blood with concentrations of 5,10,30, and 
50 ng of A-9-THC were added to glutaraldehyde treated flasks. The extraction of these 
spiked samples produced a linear curve with an r value of 0.998 (see Figure 15). The 
same experiment was run with A-9-THCA at 2, 5, 20, 50 ng/ml which also produced a 
linear curve with an r value of 0.997 (see Figure 16). 
Linearity Using Deuterated Internal Standard 
Seven 1 ml synthetic blood aliquots were spiked with 25 ng of A-9-THC-D3 as an 
internal standard and then with A-9-THC at concentrations of 0, 2, 5, 10, 25 and 50 ng/ml 
to test extraction of both analytes and determine linearity. The extraction produced a 
linear curve with a r value of 0.995 (see Figure 17). 
The same experiment was run with A-9-THCA-D3 and A-9-THCA, with the 
exception of a 1 ng sample. Results were also linear to 50 ng/ml. 
Analyses of Postmortem Samples 
The first group of postmortem samples analyzed was those secured from the 
Mississippi Crime Laboratory were those samples reported as "None Detected". These 
10 samples were analyzed on two different days using the extraction. All samples were 
found to be negative for A-9-THC. These findings are in agreement with the results 
reported by the Mississippi Crime Laboratory (see Tables 16 and 17). The negative 
findings also demonstrate that none of the solutions or hardware used during the 
experiments were or became contaminated with analytes of interest. 
Figure 15 
. 12-APR-200" 
Compound 1 name: THC 
Coefficient of Determination: 0.997082 
Calibration curve: 66.0536 * x + 0 
Response type: External Std, Area 
Curve type: Linear, Origin: Force, Weighting: Null, Axis trans: None 
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Figure 15: Calibration curve of A-9-THC extracted as a single analyte. The lvalue is 
0.997082 which exceeds the criteria of > 0.985 to be considered linear. The range is 
linear to 50 ng/ml. 
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Figure 16 
. 13-MAY-200" + 15:28:18 
Compound 1 name: THCA 
Coefficient of Determination: 0.993907 
Calibration curve: 2.98898 *x + 0 
Response type: External Std, Area 
Curve type: Linear, Origin: Force, Weighting: , Axis trans: None 
Response 
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5.0 15.0 25.0 35.0 45.0 
Figure 16: Calibration curve of A-9-THCA extracted as a single analyte. The r2 value is 
0.993907 which exceeds the criteria of > 0.985 to be considered linear. The range is 
linear to 50 ng/ml. 
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Figure 17 
, 9-APR-200" 
Compound 1 name: THC 
Coefficient of Determination: 0.998088 
Calibration curve: 0.0187199 *x + 0 
Response type: Internal std (Ref 2) , Area * (IS Cone. / IS Area) 
Curve type: Linear, Origin: Force, Weighting: Null, Axis trans: None 
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T 
35.0 
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Figure 17: Shows a linear curve of A-9-THC using the internal standard method. 
Extracted calibrators ranged from 2 - 5 0 ng/ml. 
Table 16 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\083007A 
Last Modified: Monday Bug 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THC 
Printed: Fri Bug 31 16:40:21 2007 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
083007A1 
083007A2 
083007 A3 
083007A4 
083007 A5 
083007A6 
083007A7 
083007A8 
083007A9 
083007A10 
083007A11 
083007A12 
Sample Qualifiers Cone. 
RT P/F ng/ml 
Sample ID: 0 ng/ml BLK 
NF Fail 0.0 
11.12 Pass 1.0 
Sample ID: 3 ng/ml CAL 
11.11 Pass 2.8 
11.12 Pass 1.0 
Sample ID: 10 ng/ml CAL 
11.11 Pass 10.8 
11.09 Pass 1.0 
Sample ID: 20 ng/ml CAL 
11.11 Pass 19.6 
11.08 Pass 1.0 
Sample ID: 50 ng/ml CAL 
11.11 Pass 49.6 
11.08 Pass 1.0 
Sample ID: 5 ng/ml CTRL 
11.11 Pass 4.9 
11.08 Pass 1.0 
Sample ID: FSC1A (13995) 
11.11 Pass 5.2 
11.07 Pass 1.0 
Sample ID: FSC2A (8516) 
NF Fail 0 
11.08 Pass 1.0 
Sample ID: FSC 3A (13298) 
NF Fail 0 
11.08 Pass 1.0 
Sample ID: FSC 4A (14876) 
NF Fail 0 
11.08 Pass 1.0 
Sample ID: FSC 5A (14886) 
NF Fail 0 
11.08 Pass 1.0 
Sample ID: FSC 6A (6342) 
NF Fail 0 
11.09 Pass 1.0 
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Table 16, (continued) 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
083007A13 
083007A14 
083007A15 
083007A16 
083007A17 
Sample ID: 
NF 
11.08 
Sample ID: 
NF 
11.09 
Sample ID: 
NF 
11.10 
Sample ID: 
NF 
11.09 
Sample ID: 
NF 
11.08 
FSC7A(8011) 
Fail 
Pass 
FSC8A(8106) 
Fail 
Pass 
FSC 9A (8245) 
Fail 
Pass 
FSC 10 (8464) 
Fail 
Pass 
30 ng/ml CTRL 
Pass 
Pass 
0 
1.0 
0 
1.0 
0 
1.0 
0 
1.0 
28.6 
1.0 
Table 16: Represents first run of samples from the Mississippi Crime Laboratory 
reported as "None Detected" for A-9-THC. Page 1 shows the calibrators, low control and 
5 samples. Page 2 shows 5 samples and the high control. Results match results reported 
from the Mississippi Crime Laboratory. 
71 
Table 17 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\083007B 
Last Modified: Monday Bug 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THC 
Printed: Fri Bug 3116:52:33 2007 
Sample Name: 083007B1 
THC 
THC-D3 
Sample Name: 083007B2 
THC 
THC-D3 
Sample Name: 083007B3 
THC 
THC-D3 
Sample Name: 083007B4 
THC 
THC-D3 
Sample Name: 083007B5 
THC 
THC-D3 
Sample Name: 083007B6 
THC 
THC-D3 
Sample Name: 083007B7 
THC 
THC-D3 
Sample Name: 083007B8 
THC 
THC-D3 
Sample Name: 083007B9 
THC 
THC-D3 
Sample Name: 083007B10 
THC 
THC-D3 
Sample Name: 083007B11 
THC 
THC-D3 
Sample Name: 083007B12 
THC 
THC-D3 
Sample Qualifiers ' 
RT P/F 
Sample ID: 0 ng/ml BLK 
NF Fail 
11.12 Pass 
Sample ID: 3 ng/ml CAL 
11.11 Pass 
11.12 Pass 
Sample ID: 10 ng/ml CAL 
11.11 Pass 
11.09 Pass 
Sample ID: 20 ng/ml CAL 
11.11 Pass 
11.08 Pass 
Sample ID: 50 ng/ml CAL 
11.11 Pass 
11.08 Pass 
Sample ID: 5 ng/ml CTRL 
11.11 Pass 
11.08 Pass 
Sample ID: FSC IB (13995) 
11.11 Fail 
11.07 Pass 
Sample ID: FSC 2B (8516) 
NF Fail 
11.08 Pass 
Sample ID: FSC 3B (13298) 
NF Fail 
11.08 Pass 
Sample ID: FSC 4B (14876) 
NF Fail 
11.08 Pass 
Sample ID: FSC 5B (14886) 
NF Fail 
11.08 Pass 
Sample ID: FSC 6B (6342) 
NF Fail 
11.09 Pass 
Cone. 
ng/ml 
0.0 
1.0 
3.0 
1.0 
10.1 
1.0 
19.8 
1.0 
50.3 
1.0 
5.1 
1.0 
0 
1.0 
0 
1.0 
0 
1.0 
0 
1.0 
0 
1.0 
0 
1.0 
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Table 17, (continued) 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
083007B13 
083007B14 
083007B15 
083007B16 
083007B17 
Sample ID: FSC 7B (8011) 
NF Fail 
11.08 Pass 
Sample ID: FSC 8B (8106) 
NF Fail 
11.09 Pass 
Sample ID: FSC 9B (8245) 
NF Fail 
11.10 Pass 
Sample ID: FSC 10B (8464) 
NF Fail 
11.09 Pass 
Sample ID: 30 ng/ml CTRL 
NF Pass 
11.08 Pass 
0 
1.0 
0 
1.0 
0 
1.0 
0 
1.0 
32 
1.0 
Table 17: Represents second run of samples from the Mississippi Crime Laboratory 
reported as "None Detected" for A-9-THC. Page 1 shows the calibrators, low control and 
5 samples. Page 2 shows 5 samples and the high control. Results match results reported 
from the Mississippi Crime Laboratory. 
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The next group of samples from the Mississippi Crime Laboratory run was those 
reported with quantitative values for A-9-THC. These ten samples were run on two 
separate occasions along with calibrators and controls (see Table 18). All samples were 
found to contain A-9-THC using the extraction device and all met the criteria for 
considered reportable (see Figure 18). 
Statistical analysis was performed using the Paired t test. Group A was compared 
to the values reported by the Mississippi Crime Laboratory and a significant difference 
was found. The critical value for t$\ ^ is 3.250. The statistical analysis found the Paired 
t value to be 4.384 (see Table 20). The average difference between the groups was 0.32 
ng/ml. The largest difference was 0.7 ng/ml while the smallest difference was 0.2 ng/ml. 
A second run of the same samples using a different set of devices was performed 
and analyzed statistically as stated above (see Table 19). Again a significant difference 
was found were the Paired t value was calculated to be 6.034 (see Table 21). The 
average difference in concentration was 0.35 ng/ml with a range of 0.1 to 0.6 ng/ml. 
All samples received from the Mississippi Crime Laboratory were run for 
A-9-THCA (see Figure 19). No A-9-THCA was found in two of the samples which 
agreed with values reported by the crime laboratory (see Tables 22-24). A second run 
was performed with similar results (see Tables 25-27). 
A Paired t test was performed for the A-9-THCA results in the same manner as 
for A-9-THC. The first group showed a significant with a Paired / value of 9.596 where t 
.oi(27) is 2.771 (see Table 28). The second run was subjected to the same statistical 
analysis also demonstrating a significant difference with the critical t value being 8.827 
(see Table 29). 
Table 18 
Summary Report 
C:\TurboMass\USMFSCPRO\SampleDB\082707A 
Monday Jul 27 14:48:35 2007 
C:\TurboMass\USMFSC\MethDB\THC 
Fri Aug 31 14:48:51 2007 
Sample Name: 082707A1 
THC 
THC-D3 
Sample Name: 082707A2 
THC 
THC-D3 
Sample Name: 082707A3 
THC 
THC-D3 
Sample Name: 082707A4 
THC 
THC-D3 
Sample Name: 082707A5 
THC 
THC-D3 
Sample Name: 082707A6 
THC 
THC-D3 
Sample Name: 082707A7 
THC 
THC-D3 
Sample Name: 082707A8 
THC 
THC-D3 
Sample Name: 082707A9 
THC 
THC-D3 
Sample Name: 082707A10 
THC 
THC-D3 
Sample Name: 082707A11 
THC 
THC-D3 
Sample Qualifiers < 
RT P/F 
Sample ID: 0 ng/ml CAL 1 
11.13 Fail 
11.12 Pass 
Sample ID: 3 ng/ml CAL 
11.14 Pass 
11.12 Pass 
Sample ID: 10 ng/ml CAL 
11.13 Pass 
11.12 Pass 
Sample ID: 20 ng/ml CAL 
11.13 Pass 
11.12 Pass 
Sample ID: 50 ng/ml CAL 
11.14 Pass 
11.12 Pass 
Sample ID: 5 ng/ml CTRL 
111.14 Pass 
11.12 Pass 
Sample ID: FSC11A (3330) 
11.14 Pass 
11.12 Pass 
Sample ID: FSC 12 A (4086] 
11.13 Pass 
11.12 Pass 
Sample ID: FSC 13 A (6279^ 
11.13 Pass 
11.12 Pass 
Sample ID: FSC 14 A (6349] 
11.13 Pass 
11.12 Pass 
Sample ID: FSC 15 A (6352] 
11.13 Pass 
11.12 Pass 
Cone. 
ng/ml 
0 
1.0 
3.11 
1.0 
8.71 
1.0 
19.93 
1.0 
49.88 
1.0 
5.3 
1.0 
1.8 
1.0 
10.3 
1.0 
1.4 
1.0 
2.6 
1.0 
3.3 
1.0 
Quantify Sample 
Sample List: 
Last Modified: 
Method: 
Printed: 
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Table 18, (continued) 
Sample Name: 082707A12 
THC 
THC-D3 
Sample Name: 082707A13 
THC 
THC-D3 
Sample Name: 082707A14 
THC 
THC-D3 
Sample Name: 082707A15 
THC 
THC-D3 
Sample Name: 082707A16 
THC 
THC-D3 
Sample Name: 082707A17 
THC 
THC-D3 
Table 18: Run B of A-9-THC samples from Mississippi Crime Laboratory reported with 
quantitated results. Table shows calibrators, controls and individual sample results. All 
results are from analyses conducted using the extraction device bound with monoclonal 
A-9-THC antibodies. All calibrators, controls and samples met criteria for confirmation 
and statistical analysis. 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.13 
11.12 
FSC16A(8573) 
Pass 5.0 
Pass 1.0 
FSC 17 A (1778) 
Pass 2.8 
Pass 1.0 
FSC 18 A (14275) 
Pass 3.1 
Pass 1.0 
FSC 19 A (2946) 
Pass 1.8 
Pass 1.0 
FSC 20 A (15667) 
Pass 8.1 
Pass 1.0 
30 ng/ml CTRL 
Pass 27.0 
Pass 1.0 
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Table 19 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\082707A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THC 
Printed: Fri Aug 3114:48:51 2007 
Sample Qualifiers Cone. 
Sample Name: 082707B1 
THC 
THC-D3 
Sample Name: 082707B2 
THC 
THC-D3 
Sample Name: 082707B3 
THC 
THC-D3 
Sample Name: 082707B4 
THC 
THC-D3 
Sample Name: 082707B5 
THC 
THC-D3 
Sample Name: 082707B6 
THC 
THC-D3 
Sample Name: 082707B7 
THC 
THC-D3 
Sample Name: 082707B8 
THC 
THC-D3 
Sample Name: 082707B9 
THC 
THC-D3 
Sample Name: 082707B10 
THC 
THC-D3 
Sample Name: 082707B11 
THC 
THC-D3 
RT P/F i 
Sample ID: 0 ng/ml CAL 1 
11.13 Fail 
11.12 Pass 
Sample ID: 3 ng/ml CAL 
11.14 Pass 
11.12 Pass 
Sample ID: 10 ng/ml CAL 
11.13 Pass 
11.12 Pass 
Sample ID: 20 ng/ml CAL 
11.13 Pass 
11.12 Pass 
Sample ID: 50 ng/ml CAL 
11.14 Pass 
11.12 Pass 
Sample ID: 5 ng/ml CTRL 
111.14 Pass 
11.12 Pass 
Sample ID: FSC1 IB (3330) 
11.14 Pass 
11.12 Pass 
Sample ID: FSC 12 B (4086) 
11.13 Pass 
11.12 Pass 
Sample ID: FSC 13 B (6279) 
11.13 Pass 
11.12 Pass 
Sample ID: FSC 14 B (6349) 
11.13 Pass 
11.12 Pass 
Sample ID: FSC 15 B (6352) 
11.13 Pass 
11.12 Pass 
ng/ml 
0 
1.0 
2.96 
1.0 
8.95 
1.0 
20.23 
1.0 
49.91 
1.0 
4.6 
1.0 
1.9 
1.0 
10.6 
1.0 
1.4 
1.0 
2.5 
1.0 
3.1 
1.0 
77 
Table 19, (continued) 
Sample Name: 082707B12 
THC 
THC-D3 
Sample Name: 082707B13 
THC 
THC-D3 
Sample Name: 082707B14 
THC 
THC-D3 
Sample Name: 082707B15 
THC 
THC-D3 
Sample Name: 082707B16 
THC 
THC-D3 
Sample Name: 082707B17 
THC 
THC-D3 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.13 
11.12 
FSC16B(8573) 
Pass 4.8 
Pass 1.0 
FSC17B(1778) 
Pass 2.6 
Pass 1.0 
FSC 18 B (14275) 
Pass 3.1 
Pass 1.0 
FSC 19 B (2946) 
Pass 2.0 
Pass 1.0 
FSC 20 B (15667) 
Pass 7.9 
Pass 1.0 
30 ng/ml CTRL 
Pass 31.0 
Pass 1.0 
Table 19: Run B of A-9-THC samples from Mississippi Crime Laboratory reported with 
quantitated results. Table shows calibrators, controls and individual sample results. All 
results are from analyses conducted using the extraction device bound with monoclonal 
A-9-THC antibodies. All calibrators, controls and samples met criteria for confirmation 
and statistical analysis. 
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Table 20 
Direct-Difference Statistical Evaluation of THC Values: 
Testing Group t 
Sample 
Identification 
3330 
4086 
6279 
6349 
6352 
8573 
1778 
14275 
2946 
15667 
Group Means 
CK 
MCL Results 
X1 
2 
11 
1.6 
2.9 
3.6 
5.4 
3 
3.5 
2.1 
8.3 
1X1 = 43.4 
MCL 
4.340 
Paired t Ratio 
EXP- A Results Difference 
X2 
1.8 
10.3 
1.4 
2.6 
3.3 
5 
2.8 
3.1 
1.8 
8.1 
1X2 = 40.2 
EXP-A 
4.020 
Mean Difference Between Groups (MD) 0.320 
Standard Deviation of Difference (SDD) 
£ D 2 / N = .15 
Standard Error of Differences (SED) 
Paired f Ratio = 
t oi(9) 3.250 
MD/SED = 4.384 
(Significant Difference) 
SD2 = 
MD2 = 0.102 
SED = 
DX1-X2 
0.2 
0.7 
0.2 
0.3 
0.3 
0.4 
0.2 
0.4 
0.3 
0.2 
V(£D2/N)-MD2 
V.05 = 0.22 
SDD/(VN-1) 
Difference 
Squared 
D2 
0.04 
0.49 
0.04 
0.09 
0.09 
0.16 
0.04 
0.16 
0.09 
004 
ZD2 = 1.5 
0.073 
Table 20: Direct Difference Test (Paired t Test) of first run of THC samples. 
The test identifies a significant difference between the groups indicating 
differences in results are not attributable to chance. The average difference 
between the groups is 0.32 ng/ml. 
Table 21 
Direct-Difference Statistical Evaluation of THC Values: 
Testing Group 
Sample 
Identification 
3330 
4086 
6279 
6349 
6352 
8537 
1778 
14275 
2946 
15667 
Group Means 
B 
MCL Results 
XI 
2 
11 
1.6 
2.9 
3.6 
5.4 
3 
3.5 
2.1 
8.3 
XXI =43.4 
MCL 
4.340 
Mean Difference Between Groups (MD] 
Standard Deviation of Difference (SDD 
£ D 2 / N = .15 
Standard Error of Differences (SED) 
Paired t Ratio = 
t .oi(9) 3.250 
= MD/SED = 6.034 
(Significant Difference) 
Paired t Ratio 
EXP- B Results Difference 
X2 
1.9 
10.6 
1.4 
2.5 
3.1 
4.8 
2.6 
3.1 
2 
7.9 
£X2 = 39.9 
EXP-B 
3.990 
0.350 
SD2 = 
MD2 = 0.123 
SED = 
DX1-X2 
0.1 
0.4 
0.2 
0.4 
0.5 
0.6 
0.1 
0.4 
0.1 
0.4 
V(£D2/N)-MD2 
V0.03 = 0.173 
SDD/(VN-1) 
Difference 
Squared 
D2 
0.01 
0.16 
0.04 
0.16 
0.25 
0.36 
0.01 
0.16 
0.01 
016 
£D2=1.5 
0.058 
Table 21: Direct Difference Test (Paired t Test) of second run of THC samples. 
The test identifies a significant difference between the groups indicating the 
differences in results are not attributable to chance. The average difference 
between the groups is 0.35 ng/ml. 
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Figure 18 
THC Comparisons 
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Figure 18: Comparison of A-9-THC results reported by the Mississippi Crime 
Laboratory versus separate extractions using the glutaraldehyde treated flasks with A-9-
THC monoclonal antibodies. The light blue bar represents results from the Mississippi 
Crime Laboratory while the purple and white bars represent results using the extraction 
device. Note there is a slight negative bias using the extraction device. 
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Table 22 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\082707A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Fri Aug 31 15:03:44 2007 
Sample Name: 082707A1 
THCA 
THCA-D3 
Sample Name: 082707A2 
THCA 
THCA-D3 
Sample Name: 082707A3 
THCA 
THCA-D3 
Sample Name: 082707A4 
THCA 
THCA-D3 
Sample Name: 082707A5 
THCA 
THCA-D3 
Sample Name: 082707A6 
THCA 
THCA-D3 
Sample Name: 082707A7 
THCA 
THCA-D3 
Sample Name: 082707A8 
THCA 
THCA-D3 
Sample Name: 082707A9 
THCA 
THCA-D3 
Sample Name: 082707A10 
THCA 
THCA-D3 
Sample Name: 082707A11 
THCA 
THCA-D3 
Sample Qualifiers < 
RT P/F 
Sample ID: 0 ng/ml CAL 1 
NF Fail 
13.05 Pass 
Sample ID: 5 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 10 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 20 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 50 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 10 ng/ml CTRL 
13.07 Pass 
13.05 Pass 
Sample ID: FSC 1 A (3330) 
NF Pass 
13.05 Pass 
Sample ID: FSC 2 A (4086) 
13.07 Pass 
13.05 Pass 
Sample ID: FSC 3 A (6279) 
13.07 Pass 
13.05 Pass 
Sample ID: FSC 4 A (6349) 
13.07 Pass 
13.05 Pass 
Sample ID: FSC 5 A (6352) 
13.07 Pass 
13.05 Pass 
Cone. 
ng/ml 
0 
1.0 
4.80 
1.0 
10.21 
1.0 
18.98 
1.0 
49.91 
1.0 
9.0 
1.0 
13 
1.0 
49 
1.0 
37 
1.0 
24 
1.0 
60 
1.0 
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Table 22, (continued) 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
082707A12 
082707A13 
082707A14 
082707A15 
082707A16 
082707A17 
Sample ID: FSC 6 A (8573) 
13.07 Pass 49 
13.05 Pass 1.0 
Sample ID: FSC 7 A (1778) 
13.07 Pass 58 
13.05 Pass 1.0 
Sample ID: FSC 8 A (14275) 
13.07 Pass 9 
13.05 Pass 1.0 
Sample ID: FSC 9 A (2946) 
13.07 Pass 22 
13.05 Pass 1.0 
Sample ID: FSC 10 A (15667) 
13.07 Pass 34 
13.05 Pass 1.0 
Sample ID: 30 ng/ml CTRL 
13.07 Pass 42.0 
13.05 Pass 1.0 
Table 22: Run A often A-9-THCA samples from Mississippi Crime Laboratory reported 
with quantitated results. Table shows calibrators, controls and individual sample results. 
All results are from analyses conducted using the extraction device bound with 
monoclonal A-9-THCA antibodies. All calibrators, controls and samples met criteria for 
confirmation and statistical analysis. 
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Table 23 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\083007A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Fri Aug 31 16:40:21 2007 
Sample Name: 083007A1 
THCA 
THCA-D3 
Sample Name: 083007A2 
THCA 
THCA-D3 
Sample Name: 083007A3 
THCA 
THCA-D3 
Sample Name: 083007A4 
THCA 
THCA-D3 
Sample Name: 083007A5 
THCA 
THCA-D3 
Sample Name: 083007A6 
THCA 
THCA-D3 
Sample Name: 083007A7 
THCA 
THCA-D3 
Sample Name: 083007A8 
THCA 
THCA-D3 
Sample Name: 083007A9 
THCA 
THCA-D3 
Sample Name: 083007A10 
THCA 
THCA-D3 
Sample Name: 083007A11 
THCA 
THCA-D3 
Sample Qualifiers 
RT P/F 
Sample ID: 0 ng/ml CAL 1 
NF Fail 
13.05 Pass 
Sample ID: 5 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 10 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 20 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 50 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 10 ng/ml CTRL 
13.07 Pass 
13.05 Pass 
Cone. 
ng/ml 
0 
1.0 
4.86 
1.0 
10.10 
1.0 
19.41 
1.0 
50.17 
1.0 
10.5 
1.0 
Sample ID: FSC 11 A (13995) 
NF Fail 
13.05 Pass 
0 
1.0 
Sample ID: FSC 12 A (8516) 
13.07 Pass 
13.05 Pass 
21 
1.0 
Sample ID: FSC 13 A (13298) 
13.07 Pass 
13.05 Pass 
16 
1.0 
Sample ID: FSC 14 A (14876) 
13.07 Pass 
13.05 Pass 
13 
1.0 
Sample ID: FSC 15 A (11457) 
13.07 Pass 
13.05 Pass 
20 
1.0 
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Table 23, (continued) 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
083007A12 
083007A13 
083007A14 
083007A15 
083007A16 
083007A17 
Sample ID: FSC 16 A (6342) 
13.07 Pass 7 
13.05 Pass 1.0 
Sample ID: FSC 17 A (8011) 
13.07 Pass 8 
13.05 Pass 1.0 
Sample ID: FSC 18 A (8106) 
13.07 Pass 10 
13.05 Pass 1.0 
Sample ID: FSC 19 A (8245) 
13.07 Pass 5 
13.05 Pass 1.0 
Sample ID: FSC 20 A (8464) 
13.07 Pass 7 
13.05 Pass 1.0 
Sample ID: 30 ng/ml CTRL 
13.07 Pass 41.0 
13.05 Pass 1.0 
Table 23: Run A often A-9-THCA samples from Mississippi Crime Laboratory reported 
with quantitated results. Table shows calibrators, controls and individual sample results. 
All results are from analyses conducted using the extraction device bound with 
monoclonal A-9-THCA antibodies. All calibrators, controls and samples met criteria for 
confirmation and statistical analysis. 
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Table 24 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\090407A 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Fri Sep 7 17:22:11 2007 
Sample Name: 090407A1 
THCA 
THCA-D3 
Sample Name: 090407A2 
THCA 
THCA-D3 
Sample Name: 090407A3 
THCA 
THCA-D3 
Sample Name: 090407A4 
THCA 
THCA-D3 
Sample Name: 090407A5 
THCA 
THCA-D3 
Sample Name: 090407A6 
THCA 
THCA-D3 
Sample Name: 090407A7 
THCA 
THCA-D3 
Sample Name: 090407A8 
THCA 
THCA-D3 
Sample Name: 090407A9 
THCA 
THCA-D3 
Sample Name: 090407A10 
THCA 
THCA-D3 
Sample Name: 090407A11 
THCA 
THCA-D3 
Sample Qualifiers 
RT P/F 
Sample ID: 0 ng/ml CAL 1 
NF Fail 
13.05 Pass 
Sample ID: 5 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 10 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 20 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 50 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 10 ng/ml CTRL 
13.07 Pass 
13.05 Pass 
Cone. 
ng/ml 
0 
1.0 
5.06 
1.0 
9.70 
1.0 
21.19 
1.0 
49.99 
1.0 
10.3 
1.0 
Sample ID: FSC 21 A (14621) 
13.07 Pass 
13.05 Pass 
51 
1.0 
Sample ID: FSC 22 A (16804) 
13.07 Pass 
13.05 Pass 
6 
1.0 
Sample ID: FSC 23 A (1662) 
13.07 Pass 
13.05 Pass 
20 
1.0 
Sample ID: FSC 24 A (6482) 
13.07 Pass 
13.05 Pass 
5 
1.0 
Sample ID: FSC 25 A (6701) 
13.07 Pass 
13.05 Pass 
11 
1.0 
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Table 24, (continued) 
Sample Name: 090407A12 Sample ID: FSC 26 A (8789) 
THCA NF Fail 0 
THCA-D3 13.05 Pass 1.0 
Sample Name: 090407A13 Sample ID: FSC 27 A (9500) 
THCA 13.07 Pass 5 
THCA-D3 13.05 Pass 1.0 
Sample Name: 090407A14 Sample ID: FSC 28 A (9861) 
THCA 13.07 Pass 16 
THCA-D3 13.05 Pass 1.0 
Sample Name: 090407A15 Sample ID: FSC 29 A (9873) 
THCA 13.07 Pass 23 
THCA-D3 13.05 Pass 1.0 
Sample Name: 090407A16 Sample ID: FSC 30 A (11461) 
THCA 
THCA-D3 
Sample Name: 090407A17 
THCA 
THCA-D3 
Table 24: Run A often A-9-THCA samples from Mississippi Crime Laboratory reported 
with quantitated results. Table shows calibrators, controls and individual sample results. 
All results are from analyses conducted using the extraction device bound with 
monoclonal A-9-THCA antibodies. All calibrators, controls and samples met criteria for 
confirmation and statistical analysis. 
13.07 
13.05 
Sample 
13.07 
13.05 
ID: 
Pass 
Pass 
30 ng/ml 
Pass 
Pass 
CTRL 
5 
1.0 
41.0 
1.0 
Table 25 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\082807B 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Fri Aug 31 15:03:33 2007 
Sample Name: 082807B1 
THCA 
THCA-D3 
Sample Name: 082807B2 
THCA 
THCA-D3 
Sample Name: 082807B3 
THCA 
THCA-D3 
Sample Name: 082807B4 
THCA 
THCA-D3 
Sample Name: 082807B5 
THCA 
THCA-D3 
Sample Name: 082807B6 
THCA 
THCA-D3 
Sample Name: 082807B7 
THCA 
THCA-D3 
Sample Name: 082807B8 
THCA 
THCA-D3 
Sample Name: 082807B9 
THCA 
THCA-D3 
Sample Name: 082807B10 
THCA 
THCA-D3 
Sample Name: 082807B11 
THCA 
THCA-D3 
Sample Qualifiers 
RT P/F 
Sample ID: 0 ng/ml CAL 1 
NF Fail 
13.05 Pass 
Sample ID: 5 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 10 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 20 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 50 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 10 ng/ml CTRL 
13.07 Pass 
13.05 Pass 
Sample ID: FSC 1 B (3330) 
NF Pass 
13.05 Pass 
Sample ID: FSC 2 B (4086) 
13.07 Pass 
13.05 Pass 
Sample ID: FSC 3 B (6279) 
13.07 Pass 
13.05 Pass 
Sample ID: FSC 4 B (6349) 
13.07 Pass 
13.05 Pass 
Sample ID: FSC 5 B (6352) 
13.07 Pass 
13.05 Pass 
Cone. 
ng/ml 
0 
1.0 
5.91 
1.0 
9.93 
1.0 
20.49 
1.0 
50.62 
1.0 
9.0 
1.0 
11 
1.0 
51 
1.0 
34 
1.0 
22 
1.0 
55 
1.0 
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Table 25, (continued) 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
082807B12 
082807B13 
082807B14 
082807B15 
082807B16 
082807B17 
Sample ID: FSC 6 B (8573) 
13.07 Pass 52 
13.05 Pass 1.0 
Sample ID: FSC 7 B (1778) 
13.07 Pass 59 
13.05 Pass 1.0 
Sample ID: FSC 8 B (14275) 
13.07 Pass 9 
13.05 Pass 1.0 
Sample ID: FSC 9 B (2946) 
13.07 Pass 24 
13.05 Pass 1.0 
Sample ID: FSC 10 B (15667) 
13.07 Pass 32 
13.05 Pass 1.0 
Sample ID: 30 ng/ml CTRL 
13.07 Pass 38.0 
13.05 Pass 1.0 
Table 25: Run B often A-9-THCA samples from Mississippi Crime Laboratory reported 
with quantitated results. Table shows calibrators, controls and individual sample results. 
All results are from analyses conducted using the extraction device bound with 
monoclonal A-9-THCA antibodies. All calibrators, controls and samples met criteria for 
confirmation and statistical analysis. 
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Table 26 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\083007B 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Fri Aug 31 16:52:33 2007 
Sample Name: 083007B1 
THCA 
THCA-D3 
Sample Name: 083007B2 
THCA 
THCA-D3 
Sample Name: 083007B3 
THCA 
THCA-D3 
Sample Name: 083007B4 
THCA 
THCA-D3 
Sample Name: 083007B5 
THCA 
THCA-D3 
Sample Name: 083007B6 
THCA 
THCA-D3 
Sample Name: 083007B7 
THCA 
THCA-D3 
Sample Name: 083007B8 
THCA 
THCA-D3 
Sample Name: 083007B9 
THCA 
THCA-D3 
Sample Name: 083007B10 
THCA 
THCA-D3 
Sample Name: 083007B11 
THCA 
THCA-D3 
Sample Qualifiers 
RT P/F 
Sample ID: 0 ng/ml CAL 1 
NF Fail 
13.05 Pass 
Sample ID: 5 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 10 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 20 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 50 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 10 ng/ml CTRL 
13.07 Pass 
13.05 Pass 
Cone. 
ng/ml 
0 
1.0 
4.02 
1.0 
11.10 
1.0 
18.85 
1.0 
49.81 
1.0 
8.8 
1.0 
Sample ID: FSC 11 B (13995) 
NF Fail 
13.05 Pass 
0 
1.0 
Sample ID: FSC 12 B (8516) 
13.07 Pass 
13.05 Pass 
19 
1.0 
Sample ID: FSC 13 B (13298) 
13.07 Pass 
13.05 Pass 
17 
1.0 
Sample ID: FSC 14 B (14876) 
13.07 Pass 
13.05 Pass 
12 
1.0 
Sample ID: FSC 15 B (11457) 
13.07 Pass 
13.05 Pass 
21 
1.0 
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Table 26, (continued) 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
083007B12 
083007B13 
083007B14 
083007B15 
083007B16 
083007B17 
Sample ID: FSC 16 B (6342) 
13.07 Pass 6 
13.05 Pass 1.0 
Sample ID: FSC 17 B (8011) 
13.07 Pass 6 
13.05 Pass 1.0 
Sample ID: FSC 18 B (8106) 
13.07 Pass 8 
13.05 Pass 1.0 
Sample ID: FSC 19 B (8245) 
13.07 Pass 5 
13.05 Pass 1.0 
Sample ID: FSC 20 B (8464) 
13.07 Pass 6 
13.05 Pass 1.0 
Sample ID: 30 ng/ml CTRL 
13.07 Pass 37.0 
13.05 Pass 1.0 
Table 26: Run B often A-9-THCA samples from Mississippi Crime Laboratory reported 
with quantitated results. Table shows calibrators, controls and individual sample results. 
All results are from analyses conducted using the extraction device bound with 
monoclonal A-9-THCA antibodies. All calibrators, controls and samples met criteria for 
confirmation and statistical analysis. 
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Table 27 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\090407B 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Fri Sep 7 17:22:11 2007 
Sample Name: 090407B1 
THCA 
THCA-D3 
Sample Name: 090407B2 
THCA 
THCA-D3 
Sample Name: 090407B3 
THCA 
THCA-D3 
Sample Name: 090407B4 
THCA 
THCA-D3 
Sample Name: 090407B5 
THCA 
THCA-D3 
Sample Name: 090407B6 
THCA 
THCA-D3 
Sample Name: 090407B7 
THCA 
THCA-D3 
Sample Name: 090407B8 
THCA 
THCA-D3 
Sample Name: 090407B9 
THCA 
THCA-D3 
Sample Name: 090407B10 
THCA 
THCA-D3 
Sample Name: 090407B11 
THCA 
THCA-D3 
Sample Qualifiers < 
RT P/F 
Sample ID: 0 ng/ml CAL 1 
NF Fail 
13.05 Pass 
Sample ID: 5 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 10 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 20 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 50 ng/ml CAL 
13.07 Pass 
13.05 Pass 
Sample ID: 10 ng/ml CTRL 
13.07 Pass 
13.05 Pass 
Cone. 
ng/ml 
0 
1.0 
5.38 
1.0 
11.33 
1.0 
19.92 
1.0 
50.79 
1.0 
10.4 
1.0 
Sample ID: FSC 21 B (14621) 
13.07 Pass 
13.05 Pass 
49 
1.0 
Sample ID: FSC 22 B (16804) 
13.07 Pass 
13.05 Pass 
Sample ID: FSC 23 B (1662: 
13.07 Pass 
13.05 Pass 
Sample ID: FSC 24 B (6482^ 
13.07 Pass 
13.05 Pass 
Sample ID: FSC 25 B (6701] 
13.07 Pass 
13.05 Pass 
7 
1.0 
I 
22 
1.0 
I 
5 
1.0 
) 
8 
1.0 
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Table 27, (continued) 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
090407B12 
090407B13 
090407B14 
090407B15 
090407B16 
090407B17 
Sample ID: FSC 26 B (8789) 
NF Fail 0 
13.05 Pass 1.0 
Sample ID: FSC 27 B (9500) 
13.07 Pass 5 
13.05 Pass 1.0 
Sample ID: FSC 28 B (9861) 
13.07 Pass 14 
13.05 Pass 1.0 
Sample ID: FSC 29 B (9873) 
13.07 Pass 25 
13.05 Pass 1.0 
Sample ID: FSC 30 B (11461) 
13.07 Pass 5 
13.05 Pass 1.0 
Sample ID: 30 ng/ml CTRL 
13.07 Pass 37.0 
13.05 Pass 1.0 
Table 27: Run B often A-9-THCA samples from Mississippi Crime Laboratory reported 
with quantitated results. Table shows calibrators, controls and individual sample results. 
All results are from analyses conducted using the extraction device bound with 
monoclonal A-9-THCA antibodies. All calibrators, controls and samples met criteria for 
confirmation and statistical analysis. 
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Table 28 
Direct Difference Statistical Evaluation of THCA Values: Paired t test 
Testing Group A 
Sample 
Identification 
8516 
13298 
14876 
11457 
6342 
8011 
8106 
8245 
8464 
3330 
4086 
6279 
6349 
6352 
8573 
1778 
14275 
2946 
15667 
14621 
16804 
1662 
6482 
7601 
9500 
9861 
9873 
11461 
MCL 
Results 
26 
21 
17 
28 
10 
10 
14 
6 
11 
18 
60 
43 
30 
69 
58 
68 
13 
27 
40 
63 
11 
28 
7 
13 
7 
21 
30 
6 
^Xl= 755 £X2= 
EXP-A 
Results 
21 
16 
13 
20 
7 
8 
10 
5 
7 
13 
49 
37 
24 
60 
49 
58 
9 
22 
34 
51 
6 
20 
5 
11 
5 
16 
23 
5 
604 
Difference 
D = X1-X2 
5 
5 
4 
8 
3 
2 
4 
1 
4 
5 
11 
6 
6 
9 
9 
10 
4 
5 
6 
12 
5 
8 
2 
2 
2 
5 
7 
1 
Difference 
Squared (D 
ID2= 
25 
25 
16 
64 
9 
4 
16 
1 
16 
25 
121 
36 
36 
81 
81 
100 
16 
25 
36 
144 
25 
64 
4 
4 
4 
25 
49 
1 
1053 
Group Means MCL = 26.964 EXP-A = 21.571 
Mean Difference of Groups - MCL - EXP-A 26.964-21.571= 5.393 
Standard Deviation of Difference (SDD) SDD = V (£D2/N) - MD2 
V37.607-29.083 = 2.920 
Standard Error of Difference (SED) SED = SDD/(VN-1) = 0.562 
Paired t Ratio = MD/SED = 9.596 
t oi(27)= 2.771 Significant Difference Found 
Table 28: Paired t test on the first run of A-9-THCA results reported from the Mississippi 
Crime Laboratory. The test shows a significant difference indicating the differences were 
not by chance. 
Table 29 
Direct Difference Statistical Evaluation of THCA Values: Paired t test 
Testing Group B 
Sample 
Identification 
8516 
13298 
14786 
11457 
6342 
8011 
8106 
8245 
8464 
3330 
4086 
6279 
6349 
6352 
8573 
1778 
14275 
2946 
15667 
14621 
16804 
1662 
6482 
7601 
9500 
9861 
9873 
11461 
MCL 
Results 
26 
21 
17 
25 
10 
10 
14 
6 
11 
18 
60 
43 
30 
69 
58 
68 
13 
27 
40 
63 
11 
28 
7 
13 
7 
21 
30 
6 
£X1= 755 £X2= 
EXP-B 
Results 
19 
17 
12 
21 
6 
6 
8 
5 
6 
11 
51 
34 
22 
55 
52 
59 
9 
24 
32 
49 
7 
22 
5 
8 
5 
14 
25 
5 
589 
Difference 
D = X1-X2 
7 
4 
5 
7 
4 
4 
6 
1 
5 
7 
9 
9 
8 
14 
6 
9 
4 
3 
8 
14 
4 
6 
2 
5 
2 
7 
5 
1 
Difference 
Squared (D 
ZD2= 
49 
16 
25 
49 
16 
16 
36 
1 
25 
49 
81 
81 
64 
196 
36 
81 
16 
9 
64 
196 
16 
36 
4 
25 
4 
49 
25 
1 
1266 
Group Means MCL = 26.964 EXP-A = 21.036 
Mean Difference of Groups - MCL - EXP-A 26.964 - 21.036 = 5.929 
Standard Deviation of Difference (SDD) SDD = V (£D2/N) - MD2 
V45.214-35.148 = 3.173 
Standard Error of Difference (SED) SED = SDD/(VN-1) = 0.611 
Paired t Ratio = MD/SED = 8.827 
t .oi(27) = 2.771 Significant Difference Found 
Table 29: Paired t test on the second run of A-9-THCA results reported from the 
Mississippi Crime Laboratory. The test shows a significant difference indicating the 
differences were not by chance. 
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Figure 19 
THCA Comparisons 
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Figure 19: Comparison of A-9-THCA Mississippi Crime Laboratory results versus 
results from two separate extractions using the glutaraldehyde treated flasks with A-9-
THC monoclonal antibodies. The white bars represent the results reported by the 
Mississippi Crime Laboratory while the blue and red bars represent results from the 
extraction device. Note there is a negative bias using the extraction devices. 
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The last set of samples analyzed from the Mississippi Crime Laboratory was those 
A-9-THC samples reported as "None Detected Due to Interfering Substance". These ten 
samples were treated the same as all other samples when analyzed using the extraction 
device. The ten samples were all run twice on separate days. 
Two of the samples were found to be "none detected" at 1 ng/ml. Eight of the 
samples were found to contain A-9-THC at various concentrations. The remaining eight 
samples met the requirements for confirmation and quantitation (see Tables 30 and 31). 
A Paired t test was not run for statistical comparison since there were no results 
from the Mississippi Crime Laboratory for comparison. A statistical evaluation of the 
groups themselves did not reveal a significant difference between the groups using the 
Paired t test. Mean values were 10.13 ng/ml for group A and 8.75 ng/ml for group B. 
These results are significant in that the extraction method using bound antibodies 
appears to have removed any interfering substances and allow quantitative results to be 
obtained (see Figure 20). Any interfering substances would have been removed during 
the washing steps while the analytes remained bound prior to release for analysis. 
A liquid/liquid extraction was performed in my laboratory to see if any interfering 
peaks were found (see Figure 21). There are two unidentified peaks located to the right 
of the A-9-THC peak in this extraction. These two peaks may account for the 
interference noted in the original report. The two peaks were clearly separated in this 
analysis which may be due to the fact a new column was used for the analysis and a 
different oven temperature program. A column used on a daily basis for routine analyses 
over a few months time would probably not separate these peaks at some point. 
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Table 30 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\090407B 
Last Modified: Monday Jul 27 14:48:35 2007 
Method: C:\TurboMass\USMFSC\MethDB\THC 
Printed: Fri Sep 7 17:22:11 2007 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
090407A1 
090407 A2 
090407 A3 
090407A4 
090407A5 
090407A6 
090407A7 
090407A8 
090407A9 
090407A10 
090407A11 
Sample 
RT 
Sample ID: 
NF 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.14 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.14 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
11.14 
11.12 
Sample ID: 
11.13 
11.12 
Sample ID: 
NF 
11.12 
Sample ID: 
11.13 
11.12 
Qualifiers 
P/F 
0 ng/ml CAL 1 
Fail 
Pass 
3 ng/ml CAL 
Pass 
Pass 
10 ng/ml CAL 
Pass 
Pass 
20 ng/ml CAL 
Pass 
Pass 
50 ng/ml CAL 
Pass 
Pass 
10 ng/ml CTRL 
Pass 
Pass 
Cone, 
ng/ml 
0 
1.0 
2.87 
1.0 
9.46 
1.0 
20.09 
1.0 
49.79 
1.0 
8.8 
1.0 
FSC 11 B (14621) 
Pass 7.3 
Pass 1.0 
FSC 12 B (16804) 
Pass 1.6 
Pass 
FSC 13 B (166T 
Pass 
Pass 
FSC 14 B (6482; 
Fail 
Pass 
FSC15B(670i; 
Pass 
Pass 
1.0 
) 
4.1 
1.0 
) 
0 
1.0 
) 
3.1 
1.0 
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Table 30, (continued) 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
090407A12 
090407A13 
090407A14 
090407A15 
090407A16 
090407A17 
Sample ID: FSC 16 B (8789) 
11.13 Pass 13.0 
11.12 Pass 1.0 
Sample ID: FSC 17 B (9500) 
11.13 Pass 2.3 
11.12 Pass 1.0 
Sample ID: FSC 18 B (9861) 
11.14 Pass 2.4 
11.12 Pass 1.0 
Sample ID: FSC 19 B (9873) 
11.13 Pass 2.6 
11.12 Pass 1.0 
Sample ID: FSC 20 B (11461) 
NF Fail 0 
11.12 Pass 1.0 
Sample ID: 30 ng/ml CTRL 
11.14 Pass 37.0 
11.12 Pass 1.0 
Table 30: Run A often A-9-THC samples from Mississippi Crime Laboratory reported 
as "Unable to Report Due to Interfering Substances". Table shows calibrators, controls 
and individual sample results. All results are from analyses conducted using the 
extraction device bound with monoclonal A-9-THC antibodies. All calibrators, controls 
and samples met criteria for confirmation and statistical analysis. All samples were 
reportable using the extraction device. 
Table 31 
Summary Report 
C:\TurboMass\USMFSC.PRO\SampleDB\090507B 
Monday Jul 27 14:48:35 2007 
C:\TurboMass\USMFSC\MethDB\THC 
Fri Sep 7 17:42:46 2007 
Sample Name: 090507B1 
THC 
THC-D3 
Sample Name: 090507B2 
THC 
THC-D3 
Sample Name: 090507B3 
THC 
THC-D3 
Sample Name: 090507B4 
THC 
THC-D3 
Sample Name: 090507B5 
THC 
THC-D3 
Sample Name: 090507B6 
THC 
THC-D3 
Sample Name: 090507B7 
THC 
THC-D3 
Sample Name: 090507B8 
THC 
THC-D3 
Sample Name: 090507B9 
THC 
THC-D3 
Sample Name: 090507B10 
THC 
THC-D3 
Sample Name: 090507B11 
THC 
THC-D3 
Sample Qualifiers ' 
RT P/F 
Sample ID: 0 ng/ml CAL 1 
NF Fail 
11.12 Pass 
Sample ID: 3 ng/ml CAL 
11.13 Pass 
11.12 Pass 
Sample ID: 10 ng/ml CAL 
11.14 Pass 
11.12 Pass 
Sample ID: 20 ng/ml CAL 
11.13 Pass 
11.12 Pass 
Sample ID: 50 ng/ml CAL 
11.14 Pass 
11.12 Pass 
Sample ID: 10 ng/ml CTRL 
11.13 Pass 
11.12 Pass 
Cone. 
ng/ml 
0 
1.0 
2.87 
1.0 
9.46 
1.0 
20.09 
1.0 
49.79 
1.0 
8.8 
1.0 
Sample ID: FSC 11 B (14621) 
11.13 Pass 
11.12 Pass 
7.3 
1.0 
Sample ID: FSC 12 B (16804) 
11.14 Pass 
11.12 Pass 
Sample ID: FSC 13 B (1662; 
11.13 Pass 
11.12 Pass 
Sample ID: FSC 14 B (6482; 
NF Fail 
11.12 Pass 
Sample ID: FSC 15 B(670i; 
11.13 Pass 
11.12 Pass 
1.6 
1.0 
) 
4.1 
1.0 
) 
0 
1.0 
> 
3.1 
1.0 
Quantify Sample 
Sample List: 
Last Modified: 
Method: 
Printed: 
Table 31, (continued) 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
090507B12 
090507B13 
090507B14 
090507B15 
090507B16 
090507B17 
Sample ID: FSC 16 B (8789) 
11.13 Pass 13.0 
11.12 Pass 1.0 
Sample ID: FSC 17 B (9500) 
11.13 Pass 2.3 
11.12 Pass 1.0 
Sample ID: FSC 18 B (9861) 
11.14 Pass 2.4 
11.12 Pass 1.0 
Sample ID: FSC 19 B (9873) 
11.13 Pass 2.6 
11.12 Pass 1.0 
Sample ID: FSC 20 B (11461) 
NF Fail 0 
11.12 Pass 1.0 
Sample ID: 30 ng/ml CTRL 
11.14 Pass 37.0 
11.12 Pass 1.0 
Table 31: Run B often A-9-THC samples from Mississippi Crime Laboratory reported 
as "Unable to Report Due to Interfering Substances". Table shows calibrators, controls 
and individual sample results. All results are from analyses conducted using the 
extraction device bound with monoclonal A-9-THC antibodies. All calibrators, controls 
and samples met criteria for confirmation and statistical analysis. All samples were 
reportable using the extraction device. 
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Figure 20 
THC Comparisons: Interfering Substances 
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Figure 20: Graph represents 8 of the 10 samples reported from the Mississippi Crime 
Laboratory as "Unable to Report Due to Interfering substances". Two of the samples 
were found to be negative for A-9-THC. The other 8 samples extracted using the device 
could have been quantitated and reported as shown above. 
Figure 21 
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Figure 21: Chromatogram of sample reported with an interfering 
substance following a liquid/liquid extraction in my laboratory. 
Note the two peaks to the right of the THC peak which may have 
caused the interference in the original report. 
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CHAPTER V 
DISCUSSION 
This project was designed to prove the concept of using monoclonal antibodies 
chemically bound to a solid polystyrene surface to extract A-9-THC, A-9-THCA and their 
respective internal standards from postmortem blood samples for analysis by EI+ 
GC/MS. A self-contained extraction device capable of extracting these analytes and 
removing interfering substances from postmortem blood samples would improve the 
reporting percentage of A-9-THC. Fewer reports stating "None Detected Due to 
Interfering Substance" for the presence of A-9-THC would be advantageous for medical 
examiners and toxicologists in determining if the cause of a victim's death was related in 
some manner to the use marijuana. 
Antibodies have been used for many years in various methods for both 
purification and detection of analytes of interest. Both monoclonal and polyclonal 
antibodies play a vital role in both clinical and forensic testing. A major difference 
between the disciplines is that the clinical field can use data generated directly from 
immunoassay testing. Forensic analyses require a second more specific test to confirm 
any positive immunoassay result. The most common instrument used in forensic 
laboratories to accomplish confirmations is an EI+ GC/MS. 
Monoclonal antibodies are considered more specific for the analyte of interest with fewer 
problems of cross reactivity with compounds similar in structure even those that belong 
to the same drug class. Polyclonal antibodies demonstrate the most cross reactivity and 
are used more in drug screening assays which must be followed by a confirmation 
analysis. Monoclonal antibodies were chosen for this project because of the interest was 
mainly in the extraction of A-9-THC after removal of interfering substances. 
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Polyclonal antibodies were considered for use but no vendor was found that could supply 
the polyclonal antibodies at a known concentration. 
Gas Chromatography Mass Spectrometry 
Gas chromatography mass spectrometry is a combination of two methods each 
providing unique information about an analyte. A gas chromatograph (GC) provides 
information in the form of retention times due to its ability to separate a complex mixture 
into constituent components within samples. The ability to separate such mixtures is 
accomplished by use of a mobile phase in the form of a gas and a stationary phase within 
a chromatographic column. As the gas moves the mixture through the column, the 
interaction of constituents between both phases brings about the separation. Some 
constituents are retained in the system longer than others resulting in differences in 
elution times. 
An electron impact (EI+) mass spectrometer is an instrument that provides 
information about the structure of molecules such as drugs through a fragmentation 
process. As molecules elute from the GC into the mass spectrometer, they collide with 
electrons and fragment in a specific pattern. This fragmentation pattern is consistent 
from instrument to instrument as long as the EI parameters are held the same. Such 
consistency is why this type of mass spectrometer has been chosen for performing drug 
confirmations in general and has been accepted by the legal community as the gold 
standard method. 
Two key pieces of information are given by the fragmentation pattern. First is the 
pattern itself which can be placed in mass spectral libraries for searching and 
identification purposes. Second specific ion fragments can be measured against one 
another to provide a ratio for further confidence in the results. It is these three pieces of 
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information, retention time, fragmentation pattern and ion ratios, that give the GC/MS the 
ability to positively identify a compound. 
One of the major problems with a GC/MS is the need to maintain the system so 
that the chromatography and the mass spectral patterns are free of unwanted 
contaminants. Such contaminants are compounds from extractions that tend to stay in the 
chromatographic column or co-elute with compounds of interest making fragmentation 
patterns difficult to discern. The development of an extraction device that eliminates 
most or all such interfering substances is one of the key reasons for pursuing this project. 
Initial ELISA Experiments 
Initial experiments in this project using ELISA 96 well plates demonstrated that 
antibody bound A-9-THC could be subsequently recovered for analysis by GC/MS 
following several wash steps to remove possible interfering substances. The ELISA 
experiments also showed that antibody bound A-9-THCA and both deuterated internal 
standards for GC/MS analysis could be recovered in a single extraction process. These 
experimental results gave credence to the concept of producing a device using A-9-THC 
antibodies that could be used to extract these analytes from postmortem whole blood 
while removing interfering substances. The extraction results from the ELISA plates 
were both positive but did point out some issues that had to be over come. 
One positive point as stated above was mainly that the analytes of interest 
remained bound during the protocol and could be recovered for analysis by GC/MS. This 
meant that a larger device built on the same principle should perform in the same manner. 
Analytes could be introduced, bound by antibody, washed to remove interfering 
substances and then the analyte of interest recovered for analysis. 
One of the negative issues noted was that recovery of analytes was poor and 
inconsistent at best. Since the samples were not diluted, as would be the case normally, 
poor recovery may have stemmed from an analytes inability to diffuse within the blood 
sample to the sides or bottom of the wells where the antibodies were located: ELISA 
plates are held static during the incubation period. Another reason may be that whole 
blood contains many large and complex substances that may have played a role in steric 
hindrance preventing analyte from binding the antibody. Dilution of the sample in 
ELISA testing would reduce to some degree the inability for an analyte to diffuse within 
the sample by removing many of the large molecules and at the same time increase the 
ratio of antibody to analyte enhancing chances for binding. 
Two steps were put in the extraction protocol to overcome these issues. First an 
excess of antibody was placed in each device, five meg of antibody per device. 
Secondly, the device was rotated to facilitate the movement of analyte within the device 
to increase the likelihood of contacting antibody for binding. These steps did improve 
the percent yield, 54% for A-9-THC when using the device as compared to the 28% from 
ELISA plates. The percent yield was much more consistent with the extraction device. 
Extraction Device Chosen for Experiments 
The device chosen for main portion of this project was a 25 ml Falcon® cell 
culture flask. The flask's bottom measured 12.5 cm2 which 1 ml of fluid would just 
cover. The shallow depth of a solution ensured the glutaraldehyde would contact the 
surface for binding and that the antibody solution would come into contact with the 
glutaraldehyde for chemical binding. The flask had a screw cap for closure and was large 
enough to easily decant sample into and out of the flask as well as wash and releasing 
solutions. The flat bottom was ideal for stacking the flasks on the platform 
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rotator during experiments without tilting or falling. There were some problems 
observed with this flask during the project. 
First the 90° angle formed on three sides served as a collection area for all 
solutions during rotation. A solution would naturally go to the sides as the flask rotated 
no matter how slow the rotation rate. Flasks that contain an internal angle along the sides 
may prevent fluid build up of solutions and samples around the edges and provide 
consistent coverage of the bottom area during rotation. 
A second solution would be to use a rocker to ensure a solution covered the entire 
bottom area during an experiment as it moved back and fourth. However, a means of 
securing the flasks to the rocker would have to be devised in order to place several flasks 
on at one time. 
Another problem seen with the flasks was cracking that occurred during the 
experiments. Hairline cracks would begin to appear when a releasing solvent was added 
to the flasks. The cracks were seen in the top of the flask, along the sides, but not in the 
bottom area of the flasks. At no time were the cracks of sufficient width to leak any of 
the releasing solution during incubation. 
The worst area for cracking noted was around the neck area under the cap. After 
removing the cap, often small pieces of polystyrene came off while pouring the releasing 
solvent into the glass tubes. These small pieces of polystyrene would then interfere with 
the analysis by GC/MS by clogging the Autosampler needle and/or dissolving in the 
derivatization solvent coating the injection liner and column which on occasion would 
alter the retention times of the analytes. The hairline cracks were believed due to 
pressure changes within the flasks from the heating step and the various types of aqueous 
and organic solutions used during an extraction. 
108 
The cracks under the cap were found to come more from over tightening the cap. 
When the cap was allowed to remain lose, the cracking was much less severe which in 
turn eliminated the chromatographic problems encountered from this problem. This 
same device is also sold with a vented cap which should be tried in future experiments. 
The device overall proved to be a good choice for initial experiments. There was 
sufficient surface area for antibody binding and pipetting reagents into or decanting 
reagents out of the opening was adequate. Once the problems with cracking under the 
caps were resolved, no other issues arouse from using this device. 
Antibody Binding Methods 
Two methods for attaching antibody to the device were chosen; 1) Passive 
attachment and 2) chemical attachment with glutaraldehyde. Two methods were chosen 
to test which one would be most efficient for preparing the devices, which method would 
provide the best percent yield of analyte and the one demonstrating the best robustness 
during the extraction protocol. 
First the passive adhesion was attempted by simply allowing 1 ml of the antibody 
solution containing 5 meg of antibody at a pH of 9.2 to incubate overnight at ambient 
temperature. The premise for adherence to the polystyrene surface passively is the 
alkaline pH would cause the antibody to slightly unfold exposing some hydrophobic 
regions. These regions would tend to adhere to the hydrophobic polystyrene. The 
devices were then washed three times with pH 7.2 sodium phosphate buffer followed by 
two washing of Type III water. Synthetic blood solutions containing 25 ng/ml of A-9-
THC were added to individual extraction flasks and allowed to incubate on a platform 
rotator for 1 hr. The flasks contents were poured into a biohazard container and the 
flasks rinsed with PBS. Two ml of Hexane and 0.1% acidic methanol were added to 
separate flasks as releasing solvents to test which releasing solvent worked best with the 
devices. The releasing solvents were collected, prepared and analyzed by GC/MS. 
Results of these experiments were considered unsuccessful given recovery of any 
analyte occurred only 60 percent of the time. Even when the experiments did result in 
analyte recovery, percent yield of analyte was inconsistent to the point linearity, LOQ or 
LOD could not be determined. The main problem with this type of immobilization is 
leaching of the antibody during removal of the analyte of interest (Nisnevitch and Frier, 
2001). After several attempts to improve passive antibody binding by longer incubation 
times, use of a detergent and altering pH values, this procedure was abandoned. 
The second method chosen was to bind gluteraldehyde to the flask bottom 
surface using the method of Hermanson, et al. (1992). The initial protocol called for 
using 2% glutaraldehyde in a pH 5.0 sodium phosphate buffer. One ml of this solution 
was added to four extraction devices and allowed to incubate for 4 hours at room 
temperature. The devices were then washed 5 times with the pH 5.0 phosphate buffer. 
Each device was tapped over paper towels to remove excess liquid and then allowed to 
drain for 10 minutes. 
The second step was adding one ml of the antibody solution containing 5 meg of 
antibody per ml of a sodium phosphate buffer, pH 8.0, was added to each device and 
incubated at 37° C for a minimum of 3 hr. Each device was then washed 3 times with a 
sodium phosphate buffer, pH 8.0, tapped to remove excess buffer and allowed to drain 
for lOmin. 
One ml samples of synthetic blood containing no drug were added to two devices 
and 1 ml samples containing 25 ng/ml A-9-THC were added to two other devices. All 
four devices were carried through the extraction protocol. The four devices were washed 
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5 times with a sodium phosphate buffer, pH 7.2 and allowed to drain for 30 min. Two ml 
of hexane was added to one of the negative and one of the spiked devices and 0.1% acidic 
methanol was added to the other two devices in order to determine which solvent 
produced the best recovery of analyte using the flasks as well as which resulted in the 
least interference with the GC/MS assay. 
Hexane proved to be the best releasing reagent with an analyte yield of 28% as 
compared to a 17% yield with acidic methanol. The two negative samples did not show 
any recovery of A-9-THC. This experiment was repeated three times with similar results. 
In order to raise the percent yield, the glutaraldehyde solution was increased to a 
5% solution for binding the antibodies within the device. This change did increase the 
percent yield from 28% to an average of 38% using hexane as the releasing solvent. 
Again hexane was a better releasing solvent than 0.1% acidic methanol. Hexane also 
provided a cleaner extract when compared to the 0.1% acidic methanol when inspecting 
glass injection liners following a series of injections. The difference may be in the 
manner by which the antibodies are bound to the polystyrene. The binding of antibodies 
in ELISA plates from Immunalysis is proprietary and probably does not release any 
antibody during the releasing step whether using hexane or acidic methanol. The same 
may not be true for antibodies bound to polystyrene using glutaraldehyde. 
A concern using this type of attachment is the orientation and spread of the 
antibodies over the bottom surface of the flasks. The antibodies can orient in any 
direction given the attachment between the glutaraldehyde and the antibody uses amine 
groups. Amine groups are available for bonding in many areas of the antibody including 
the terminal ends where the binding sites are located. There is also no way to control 
exactly where the antibodies bind the glutaraldehyde as to position in the 12.5 cm2 
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surface area of the flask bottom. This is the reason for having to add what is considered 
an excess of antibody, 5 meg, to each device to extract approximately 100 - 200 ng of 
analytes. 
Experiments Using Synthetic Whole Blood 
Initial experiments used synthetic whole blood purchased from Immunalysis with 
the ELISA kits. The lypholized whole blood was prepared according to instructions 
received in the ELISA kits and used for initial experiments of percent yield and linearity 
studies with the new devices. The synthetic blood had a homogeneous consistency with 
no clots and showed no precipitation when analytes in methanol solutions were added. 
Linearity was established from 0 to 50 ng/ml using internal standards for both 
analytes. Limit of Detection (LOD) for A-9-THC was calculated to be 1.0 ng/ml. The 
Limit of Quantitation (LOQ) was found to be 1.0 ng/ml which was higher than desired 
but at an acceptable level for reporting of A-9-THC. LOD for A-9-THCA was found to 
be 2.0 ng/ml with a LOQ of 3.0 ng/ml. The values for A-9-THCA are excellent for this 
analyte for most laboratories do not report A-9-THCA present or give a quantitative value 
below 5 ng/ml. 
Use of the synthetic blood bolstered the concept that the device was working as 
designed and that future research would only make the device better and more efficient. 
This was until testing of actual samples began. 
Experiments Using Actual Postmortem Samples 
Thirty postmortem samples were secured from the Mississippi Crime Laboratory 
that had been previously analyzed for A-9-THC and A-9-THCA. Ten of the samples had 
been found to contain no A-9-THC at 0.5 ng/ml, ten of the samples had been reported 
with A-9-THC present plus quantitated and ten samples had been reported as "None 
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Detected Due to Interfering Substance". Twenty eight of the samples reported A-9-
THCA as present and quantitated with two samples being reported as "None Detected at 
5 ng/ml". This group of samples provided an excellent challenge to using the new device 
for they covered all aspects of the original experimental design. 
Initially five devices were made and 1 ml of postmortem samples added to each 
and run through the protocol simply to establish both analytes would be recovered. 
Surprisingly, only two of the five had any recovery of analytes and the percent yield was 
approximately half that seen with the synthetic blood samples. Five more devices were 
prepared and the experiment repeated after each individual postmortem sample was 
mixed over night. The results of the second experiment were basically the same as the 
first with the exception of A-9-THCA being recovered from a third sample. No internal 
standards were added for quantitations during these first two experiments so no 
information was gained concerning those two analytes during the initial experiments with 
postmortem samples. 
New batches of all buffers and the 5% glutaraldehyde were made for a third 
experiment on the postmortem samples. Two devices were prepared and 1 ml of a 
postmortem sample reported as "None Detected" was spiked with 25 ng/ml A-9-THC and 
placed in one device and 1 ml of a postmortem sample reported as "None Detected" was 
spiked with 25 ng/ml A-9-THCA and placed in the second device. The two devices were 
carried through the protocol with fresh reagents. Recovery of the A-9-THC was still poor 
and the sample spiked with A-9-THCA demonstrated no recovery of analyte. 
At this point, experiments were conducted again using the synthetic blood to 
reaffirm original results and test the antibody solution for deterioration of the antibody. 
Two devices were used spiked as described in the previous paragraph. Analytes from 
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both devices were recovered as expected using the synthetic blood. This meant that the 
problem was with the postmortem samples themselves and not any reagents, antibody or 
prepared devices. 
Wong et al. (1982) did a study on the effect of long term storage of A-9-THC in 
blood and serum. Their study looked at the storage of spiked samples of A-9-THC in 
whole blood and serum in several storage environments and at several temperatures 
ranging from -20° to 60° C over a 25 week period. No appreciable loss of A-9-THC was 
found at any storage temperature or environment until around week 17. After this point, 
recovery of A-9-THC from blood or serum became inconsistent and was not achievable 
after week 25. The article's authors concluded that the inability to recover the analyte 
was not due to degradation of the molecule or surface absorption onto the container, but 
rather a binding of the molecule to degrading proteins in the sample. 
A method to separate the drug from any protein had to be developed to release 
any bound A-9-THC. Two solvents were chosen to attempt to denature proteins and 
allow recovery of both A-9-THC and A-9-THCA; 1) methanol and 2) acetonitrile. 
A 1 ml sample of the synthetic blood spiked with 25 ng/ml A-9-THC was placed 
in a 16X125 mm screw cap borosilicate glass tube. While vortexing the sample, 1 ml 
methanol was slowly added one drop at a time. Vortexing continued for 30 seconds after 
the last drop of methanol was added. The sample was then centrifuged at 3000 rpm for 
25 minutes. The sample was removed and checked to see if a pellet was present and the 
supernatant was fairly transparent. The supernatant was then transferred to a clean 
16X125 mm tube and stored at 4° C for later analysis. The same procedure was 
conducted using acetonitrile in place of methanol. The acetonitrile supernatant was more 
transparent than the methanol sample. The acetonitrile sample was handled in the same 
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manner and stored for later analysis. 
Two devices were prepared to use with the samples prepared above and taken 
through the protocol. Recovery of analyte was achieved using both solvents with more 
analyte being recovered with acetonitrile, however recovery of analytes were less than 
with previous runs. This raised the question of were the organic solvents were reacting 
with the antibodies resulting in the poor recovery of analytes. 
The procedure was performed two more times using acetonitrile only with spiked 
synthetic blood samples. A new step was added following centrifugation and transfer of 
the supernatant to a clean tube. The acetonitrile was evaporated almost to dryness under 
a vacuum at 50° C. To each of the two tubes was added 1 ml of a 0.5% saline solution 
and the tubes vortexed a second time. The tubes were then centrifuged at 3000 rpm for 
25 minutes. The supernatant was transferred into a device which was carried through the 
protocol. Recovery of the analyte from both tubes improved and was found to be in the 
50% range as compared to 38% in the initial experiments using the synthetic blood. 
Two postmortem negative samples were taken and spiked with 25 ng/ml A-9-
THC and treated with the acetonitrile procedure. The samples were then carried through 
the extraction protocol. Results matched percent yield studies conducted with the 
synthetic blood samples using this same procedure. The percent yield increase held true 
for A-9-THCA experiments using the acetonitrile procedure prior to extraction. From 
this point forward all experiments were conducted using the acetonitrile procedure to 
prepare the samples. 
Antibody Binding Studies Using Extraction Device 
Seven extraction devices were prepared using the glutaraldehyde protocol and 
then tested using ELISA reagents to determine the approximate binding capacity for A-9-
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THC and A-9-THCA of a device. This experiment was conducted five different times. 
Samples spiked from 10 to 1000 ng/ml were used plus a negative sample. Absorbance 
values from the experiments followed an inverse curve as expected. Those devices 
containing the lowest concentration of analyte showed the largest range of absorbance 
readings while increasing the concentration, narrowed the absorbance values seen. 
As the antibody sites became saturated with analyte, fewer of the enzyme-tagged 
THC derivatives were able to be bound and subsequently washed out of the devices prior 
to adding the color reagent. The fewer the THC derivatives bound within a device the 
expectation would be decreased to no color change. This is exactly what is shown by the 
experiments. One would also expect the absorbance value ranges to become narrower as 
the concentration of analyte increased for the same reasons. This is also shown in the 
experimental results. 
The devices showed the ability to bind a concentration of A-9-THC of between 
200 and 500 ng/ml. At 1000 ng/ml, the device was found to be totally saturated with no 
color change noted. The absorbance range at 500 ng/ml was 0.0097 to 0.0433 which 
indicates that this concentration probably saturates most all antibody sites since the 
absorbance values differ by only 0.0336. At the 200 ng/ml concentration, absorbance 
demonstrated a range difference of 0.1360 which indicates that binding sites were still 
available. 
For each of the 35 devices to show a binding capacity of 200 ng/ml or more is 
adequate for performing extractions on postmortem blood samples. The concentration of 
A-9-THC usually seen in postmortem blood samples is less than 20 ng/ml: The highest 
value that this researcher has seen in a postmortem blood sample was 53 ng/ml in an 
individual who was smoking marijuana at the time of death. Taking into account the 
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addition of 25 ng/ml of A-9-THC-D3 and 50 ng/ml of A-9-THCA-D3, this totals less than 
100 ng/ml which leaves sufficient binding capacity for extracting A-9-THCA. The 35 
devices made for this experiment demonstrates that this protocol is consistent from batch 
to batch for extractions of both analytes. 
Percent Yield Studies 
Percent yield studies were conducted to determine the average concentration 
recovered from a spiked 1 ml sample as compared to a direct standard. These 
experiments were conducted for A-9-THC and A-9-THCA at 25 ng/ml separately using 
100 prepared devices (50 for each analyte) over a ten day timeframe. The average 
percent yield for A-9-THC was 54% with a range of 50 - 61%. A-9-THCA had a 47% 
yield with a range of 37 - 52%. These experiments were conducted using the acetonitrile 
clean up protocol which had previously been shown to provide the best percent yield 
from extraction devices. These results are fairly consistent in regards again to the making 
of extraction devices but need to be improved with future research. A standard statistical 
test of reliability was performed for both analytes to ensure the values obtained met 
Cronbach's alpha for reliability within each experiment. Both A-9-THC and A-9-THCA 
met the criteria having alpha scores of 0.954 and 0.803 respectfully. 
Research using different chemical linking molecules or choosing a different 
device that would allow for consistent orientation of antibodies, possess fewer variables 
for spread of bound antibodies and/or are more resistant to organic solvents and heat are 
all areas for future research in drug extractions from difficult matrices. Improvement of 
extraction efficiency would also allow lower detection and quantitation levels to be 
achieved. 
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Effect ofA-9-THC Concentration on Binding ofA-9-THCA 
A study was conducted where both A-9-THC and A-9-THCA were added together 
in the same device at equal concentrations to establish if the there was an effect on the 
binding capacity of A-9-THCA. Concentrations ranged from 10 - 150 ng for each 
analyte. Percent yield of both analytes were practically the same until the concentration 
of A-9-THC was greater than 60 ng. The percent yield of A-9-THCA began to fall above 
this level and continued to fall as the concentration of A-9-THC was further increased. 
When the concentration of A-9-THC was 150 ng approximately 30 ng of A-9-THCA was 
recovered even though 150 ng of A-9-THCA had been added to the device. 
These results speak to the specificity of the antibody for A-9-THC as compared to 
A-9-THCA. However, this finding would have limited impact on using the device as an 
extraction method for both analytes. It must be pointed out again that these levels of both 
analytes would not be found in a real sample. 
Linearity Studies 
Two types of linearity studies were performed during this project. The first was 
extracting each analyte singly and the second was an extraction of both analytes along 
with their respective internal standards. 
Negative blood samples were spiked at concentrations of 5, 10, 25 and 50 ng/ml 
of A-9-THC. The samples were extracted and then analyzed by GC/MS. Extraction of 
A-9-THC gave a linear curve with an r2 of 0.998. Extraction of A-9-THCA gave a linear 
curve with a r of 0.997. No attempt was made to extend the curve using the single 
analytes since no real extraction would be done without using deuterated internal 
standards. 
The linear curves for both analytes with their internal standards was performed by 
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spiking negative blood samples at 2, 5,10,25 and 50 ng/ml of A-9-THC and A-9-THCA 
along with 25 ng/ml A-9-THC-D3 and 50 ng/ml A-9-THCA-D3. Limiting the curve to 
50 ng/ml was due to the loss of A-9-THCA when A-9-THC concentration went above 60 
ng/ml. Both analytes were extracted simultaneously in runs using the extraction device. 
Results of the curves were r2 of 0.995 for A-9-THC and 0.997 for A-9-THCA. 
These experiments demonstrate the ability to extract both analytes of interest from 
a single device which means that real samples can be handled in the same manner with 
both analytes being extracted in one run. This is the only extraction method this 
researcher is aware of where both analytes are extracted in a single step. 
First Analysis of True Postmortem Samples 
Analyses of postmortem samples received from the Mississippi were divided into 
four groups. The first group analyzed for A-9-THC was those samples reported as "None 
Detected". The ten samples were prepared using the acetonitrile protocol and then 
extracted using prepared devices the same day. A set of calibrators ranging from 3 - 5 0 
ng/ml and two controls at 5 and 30 ng/ml were also run with the samples. The calibration 
curve met the criteria for being linear and the controls were within ± 20% of expected 
values. The samples were run twice on separate days under the same conditions. 
Both groups agreed with the findings reported by the Mississippi Crime 
Laboratory. There was no A-9-THC detected in any of the 10 samples during either run 
(see Figures 22 and 23). Internal standards added were recovered and met the criteria for 
being acceptable (see Figures 24 and 25). 
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Figure 22 
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Figure 22: Represents a negative sample of A-9-THC as reported by the 
Mississippi Crime Laboratory. The three required ions are not present as 
indicated by failure of the computer to integrate and would not fit any 
confirmation criteria. 
Figure 23 
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Figure 23: Represent a negative sample from the Mississippi Crime Laboratory 
for A-9-THCA. The three ions are obviously not present and would not meet 
criteria for confirmation. 
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Figure 24: Internal standard ions recovered from extraction of negative A-9-THC 
sample seen in figure 22. Note the ions passed criteria for being acceptable. 
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Figure 25: Internal standard ions recovered from negative A-9-THCA sample 
seen in figure 23. Note the ions met criteria for being considered acceptable. 
123 
The second group of samples analyzed was those reported with A-9-THC present 
and quantitated (see Figures 26 and 27). Paired t results from the first run were compared 
to a critical value for t ,oi(9) was 3.250. The Paired t value found was 4.384 indicating a 
significant difference between the results. The samples extracted with the device showed 
a negative bias averaging 0.32 ng/ml. The second group analyzed also showed a 
significant difference between the groups as well with a Paired / value of 6.034. A 
negative bias was noted again with a slight average difference of 0.35 ng/ml. 
These results indicate the device is capable of extracting A-9-THC and the results 
obtained are comparable to results from another laboratory using a different extraction 
technique. This is a critical element of the project for it clearly demonstrates the ability 
to accurately quantitate A-9-THC that is important in postmortem blood samples because 
this is the compound that is responsible for impairment of the central nervous system. 
The third group of samples to discuss is the finding for A-9-THC A which was 
analyzed twice for all 30 samples. Two of the 30 samples were found to be negative 
which agrees with the reports from the Mississippi Crime Laboratory. The other 28 
samples were reported to contain A-9-THCA (see Figures 28 and 29). Those samples 
that had a reported value above 50 ng/ml were diluted in order to bring them in the linear 
range of the assay and then multiplied by the dilution factor for their final result. 
The A-9-THCA samples were analyzed 10 at a time along with their respective A-
9-THC analyses. Statistical analysis of the first group of 28 showed a significant 
difference between the results obtained with the extraction device and the results reported 
by the Mississippi Crime Laboratory as was described in the results chapter. 
Figure 26 
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Figure 26: Shows the three ions present from a sample whose concentration was 
calculated to be 2.0 ng/ml of A-9-THC. All three ions meet ration criteria for 
being considered confirmed and quantitation acceptable. This is sample 2946 
from Mississippi Crime Laboratory. 
Figure 27 
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Figure 27: Internal standards ions recovered with sample seen in figure 26. 
Figure 28 
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Pass/Fail: 
THCA 
13.08 mm 
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Time 
13.100 
D90907AZ7A 
13.100 
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Figure 28: A-9-THCA extracted from Mississippi Crime Laboratory sample 
2946. Note all three ions are present and the result is 22 ng/ml. This analyte was 
extracted at the same time as the A-9-THC extracted from the same device shown 
in Figure 26. 
Figure 29 
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Figure 29: A-9-THCA internal standard ions from sample 2946 shown in figure 
28. 
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There was a negative bias noted averaging 5.4 ng/ml less than the reported values. 
The calculated mean for the first group was 21.6 with a range of 5 - 60 ng/ml. 
The second analytical run also showed a significant difference between the results with a 
mean of 21 ng/ml again with a negative bias of 5.9 ng/ml. The mean value for the 
reported values was 27.0 with a range of 6 - 69 ng/ml. 
There were four samples that had to be diluted X2 because of values above the 
linear range of 50 ng/ml. All eight results came back well within 20% of the reported 
value. Given A-9-THCA only indicates previous use and does not apply to impairment, 
these values would be acceptable for reporting. 
The last A-9-THC group to be discussed was the samples reported as "None 
Detected Due to Interfering Substance". This group is considered the most critical of all 
the analyses run for it tests whether the extraction process actually removed the 
interfering substances. 
Two of the ten samples were found to contain no A-9-THC at a concentration of 1 
ng/ml. The other eight samples did confirm the presence of and give quantitative results 
for A-9-THC. These findings indicate that any substance that interfered with the analysis 
of these samples when performed by another laboratory using a different extraction 
technique had been removed. 
The extraction device performed as anticipated proving an extraction approach 
using such device with bound antibody for a specific drug is a viable option. The device 
proved to be simple to use, of low cost and not require the multiple steps encountered 
with today's common extraction procedures. 
One of the main obstacles encountered during the project was the time required to 
bind the antibodies to the polystyrene flask in preparation for extractions. The initial step 
was a four hour incubation to bind the glutaraldehyde to the flask followed by a three 
hour incubation period of binding the antibodies to the glutaraldehyde. Take into 
account the time for washing steps in between the two incubation periods along with the 
minimum of one hour for incubation of the sample, 20 min wash in hexane to release the 
analytes, 20 min evaporation of the hexane and one hour incubation for derivatization, 
the total time from start to instrument was approximately 10 hours. Research should be 
performed to establish if any of these times could be shortened by using different binding 
chemistries or different type devices. 
Future projects for other drugs using this approach could be LSD, 6-
monoacetylmorphine, morphine, oxycodone, alprazolam and others that demonstrate 
impairment or toxicity at concentrations in the ng/ml range. Extraction devices that 
would hold specific antibodies to different drugs within the same device need to be 
investigated. 
Such projects are anticipated thesis projects and research for students pursuing 
graduate degrees in the field of forensic science with an emphasis in the areas of 
Toxicology or Implied Consent. 
The new device and process could bring to the field of toxicology the advances 
enjoyed in biochemistry and molecular biology in separation and purification of proteins 
and DNA from complex matrices using the technique of affinity chromatography. With 
no or reduced interfering substances to deal with, instrumentation maintenance and 
supply cost would be reduced by as much as 50% and analytical extraction procedures 
could be shortened by several hours, thus, improving turn around time for data reporting. 
Training of laboratory personnel on this new device would be extremely simple 
with basically no learning curve involved. The only steps are adding the buffered sample, 
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incubation, rinsing the device and then releasing the drug for analysis. From that point 
forward, the steps are the same as any other extraction protocol for analyzing drugs on 
chromatographic instruments. 
There is an excellent opportunity for commercial production of the device and 
making it available for purchase and use by all laboratories dealing with postmortem drug 
testing. The device as envisioned is not costly to produce. The device also eliminates the 
use and disposal of high volumes of organic solvents, buffers and glassware presently 
used for extraction procedures. Savings on instrument maintenance and supplies would 
offset costs even further. 
The device also lends itself to extraction of substances other than drugs from 
complex matrices provided a specific antibody can be produced against the antigen of 
interest. Furthermore, the device is small and portable which makes it practical for use in 
the field for collection of suspected toxins or chemicals for later analysis. 
APPENDIX 
Figure 30 
Compound 1 name: THC 
Coefficient of Determination: 0.994990 
Calibration curve: 0.0377391 * x + 0 
Response type: Internal Std ( Ref 2 ), Area * (IS Cone. / IS Area ) 
1.89n 
Response-
0 y11111 i i 1111111111 i i 11111111111111111111111111 ii 111 ng/ml 
5.0 15.0 25.0 35.0 45.0 
Figure 30: A calibration curve for A-9-THC from run 083007A. 
Figure 31 
Compound 1 name: THCA 
Coefficient of Determination: 0.996439 
Calibration curve: 0.0280418*x + 0 
Response type: Internal Std ( Ref 2 ), Area * (IS Cone. / IS Area ) 
1.43-
Response-I 
0 Yi 1111111111111111111111111111111111111111111111111 n g / m l 
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Figure 31: A calibration curve for A-9-THCA from run 082707A. 
Table 32 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSCPRO\SampleDB\061207 
Last Modified: Monday May 27 08:18:39 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Wed Jun 12 09:10:30 2007 
Sample Name: 0612071 
THC 
THC-D3 
Sample Name: 0612072 
THC 
THC-D3 
Sample Name: 0612073 
THC 
THC-D3 
Sample Name: 0612074 
THC 
THC-D3 
Sample Name: 0612075 
THC 
THC-D3 
Sample Name: 0612076 
THC 
THC-D3 
Sample Name: 0612077 
THC 
THC-D3 
Sample Name: 0612078 
THC 
THC-D3 
Sample Name: 0612079 
THC 
THC-D3 
ample Name: 06120710 
THC 
THC-D3 
Sample Name: 06120711 
THC 
THC-D3 
Sample Qualifiers 
RT P/F 
Sample ID: 2 ng/ml CAL 
11.11 Pass 
11.12 Pass 
Sample ID: Spike 1 
11.10 Pass 
11.12 Pass 
Sample ID: Spike 2 
NF Fail 
11.12 Pass 
Sample ID: Spike 3 
11.09 Pass 
11.12 Pass 
Sample ID: Spike 4 
NF Fail 
11.12 Pass 
Sample ID: Spike 5 
NF Fail 
11.12 Pass 
Sample ID: Spike 6 
11.11 Pass 
11.12 Pass 
Sample ID: Spike 7 
NF Fail 
11.12 Pass 
Sample ID: Spike 8 
NF Fail 
11.12 Pass 
Sample ID: Spike 9 
NF Fail 
11.12 Pass 
Sample ID: Spike 10 
NF Fail 
11.12 Pass 
Cone. 
ng/ml 
2.0 
1.0 
0.6 
1.0 
0 
1.0 
0.2 
1.0 
0 
1.0 
0 
1.0 
0.4 
1.0 
0 
1.0 
0 
1.0 
0 
1.0 
0 
1.0 
Table 32: Experiment for LOD at 0.5 ng/ml. The first injection was a 2.0 ng/ml 
extracted standard. The 10 subsequent injections were to determine the Limit of 
Detection for A-9-THC. Samples failed 7 out of 10 injections. 
Table 33 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\061207 
Last Modified: Monday May 27 08:18:39 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Wed Jun 12 19:21:00 2007 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
Sample Name: 
THC 
THC-D3 
06120712 
06120713 
06120714 
06120715 
06120716 
06120717 
06120718 
06120719 
06120720 
06120721 
06120722 
Sample Qualifiers 
RT P/F 
Sample ID: 2 ng/ml CAL 
11.11 Pass 
11.12 Pass 
Sample ID: Spike 1 
11.10 Pass 
11.12 Pass 
Sample ID: Spike 2 
11.11 Pass 
11.12 Pass 
Sample ID: Spike 3 
11.09 Pass 
11.12 Pass 
Sample ID: Spike 4 
11.10 Pass 
11.12 Pass 
Sample ID: Spike 5 
11.10 Pass 
11.12 Pass 
Sample ID: Spike 6 
11.11 Pass 
11.12 Pass 
Sample ID: Spike 7 
11.10 Pass 
11.12 Pass 
Sample ID: Spike 8 
11.10 Pass 
11.12 Pass 
Sample ID: Spike 9 
11.11 Pass 
11.12 Pass 
Sample ID: Spike 10 
11.10 Pass 
11.12 Pass 
Cone. 
ng/ml 
2.0 
1.0 
0.8 
1.0 
1.1 
1.0 
0.9 
1.0 
1.2 
1.0 
1.2 
1.0 
1.1 
1.0 
0.9 
1.0 
0.8 
1.0 
1.1 
1.0 
1.1 
1.0 
Table 33: Experiment for LOQ at 1.0 ng/ml. The first injection was a 2.0 ng/ml 
extracted standard. The 10 subsequent injections were to determine the Limit of 
Quantitation for A-9-THC. Analysis gave a mean of 1.02 ng/ml. All samples met 
criteria 10 out of 10 injections. 
Table 34 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\061207 
Last Modified: Monday May 27 08:18:39 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Wed Jun 12 09:41:07 2007 
Sample Name: 0612071 
THCA 
THCA-D3 
Sample Name: 0612072 
THCA 
THCA-D3 
Sample Name: 0612073 
THCA 
THCA-D3 
Sample Name: 0612074 
THCA 
THCA-D3 
Sample Name: 0612075 
THCA 
THCA-D3 
Sample Name: 0612076 
THCA 
THCA-D3 
Sample Name: 0612077 
THCA 
THCA-D3 
Sample Name: 0612078 
THCA 
THCA-D3 
Sample Name: 0612079 
THCA 
THCA-D3 
Sample Name: 06120710 
THCA 
THCA-D3 
Sample Name: 06120711 
THCA 
THCA-D3 
Sample Qualifiers 
RT P/F 
Sample ID: 5 ng/ml CAL 
13.09 Pass 
13.07 Pass 
Sample ID: Spike 1 
13.09 Pass 
13.07 Pass 
Sample ID: Spike 2 
13.08 Pass 
13.07 Pass 
Sample ID: Spike 3 
13.09 Pass 
13.06 Pass 
Sample ID: Spike 4 
13.09 Pass 
13.07 Pass 
Sample ID: Spike 5 
13.09 Pass 
13.07 Pass 
Sample ID: Spike 6 
13.08 Pass 
13.06 Pass 
Sample ID: Spike 7 
13.10 Pass 
13.08 Pass 
Sample ID: Spike 8 
13.09 Pass 
13.07 Pass 
Sample ID: Spike 9 
13.09 Pass 
13.07 Pass 
Sample ID: Spike 0 
13.09 Pass 
13.06 Pass 
Cone. 
ng/ml 
5.0 
1.0 
0.8 
1.0 
1.5 
1.0 
0.9 
1.0 
1.7 
1.0 
1.1 
1.0 
2.1 
1.0 
1.9 
1.0 
0.8 
1.0 
1.1 
1.0 
1.5 
1.0 
Table 34: Experiment for LOD at 2.0 ng/ml. The first injection was a 5.0 ng/ml 
extracted standard. The 10 subsequent injections were to determine the Limit of 
Detection for A-9-THCA. All samples met criteria 10 out of 10 injections. 
Table 35 
Quantify Sample Summary Report 
Sample List: C:\TurboMass\USMFSC.PRO\SampleDB\061207 
Last Modified: Monday May 27 08:18:39 2007 
Method: C:\TurboMass\USMFSC\MethDB\THCA 
Printed: Wed Jun 12 09:41:07 2007 
Sample Name: 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name 
THCA 
THCA-D3 
Sample Name 
THCA 
THCA-D3 
Sample Name: 
THCA 
THCA-D3 
Sample Name 
THCA 
THCA-D3 
Sample Name 
THCA 
THCA-D3 
Sample Name 
THCA 
THCA-D3 
Sample Name 
THCA 
THCA-D3 
Sample Name 
THCA 
THCA-D3 
Sample Name 
THCA 
THCA-D3 
06120712 
06120713 
: 06120714 
06120715 
06120716 
06120717 
06120718 
06120719 
06120720 
06120721 
06120722 
Sample Qualifiers 
RT P/F 
Sample ID: 5 ng/ml CAL 
13.09 Pass 
13.07 Pass 
Sample ID: Spike 1 
13.09 Pass 
13.07 Pass 
Sample ID: Spike 2 
13.08 Pass 
13.07 Pass 
Sample ID: Spike 3 
13.09 Pass 
13.06 Pass 
Sample ID: Spike 4 
13.09 Pass 
13.07 Pass 
Sample ID: Spike 5 
13.09 Pass 
13.07 Pass 
Sample ID: Spike 6 
13.08 Pass 
13.06 Pass 
Sample ID: Spike 7 
13.10 Pass 
13.08 Pass 
Sample ID: Spike 8 
13.09 Pass 
13.07 Pass 
Sample ID: Spike 9 
13.09 Pass 
13.07 Pass 
Sample ID: Spike 10 
13.09 Pass 
13.06 Pass 
Cone. 
ng/ml 
5.0 
1.0 
2.9 
1.0 
3.2 
1.0 
2.8 
1.0 
3.1 
1.0 
3.1 
1.0 
3.0 
1.0 
2.8 
1.0 
2.9 
1.0 
3.1 
1.0 
3.2 
1.0 
Table 35: Experiment for LOQ at 3.0 ng/ml. The first injection was a 5.0 ng/ml 
extracted standard. The 10 subsequent injections were to determine the Limit of 
Quantitation for A-9-THCA. All samples met criteria 10 out of 10 injections. 
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Figure 32: Chromatographic peak and selected ions for A-9-THC from sample 
1662. This sample was reported with interfering substances and unable to quantitate. 
Using the device, there were no interfering substances noted and 4.1 ng/ml was 
found present. 
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Figure 33: A sample reported with interfering substances. This is 
sample 6482 from the Mississippi crime Laboratory. There are no inter-
fering substances noted and the sample was found to be negative for 
A-9-THC. 
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Figure 35: Sample 2946 for A-9-THCA. 24 ng/ml were found present in this 
analysis as compared to 27 ng/ml reported by the Mississippi Crime Laboratory. 
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